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Abstract
Crohn’s disease is a chronic inflammatory condition of the human gastrointesti-
nal tract. It affects approximately one in five hundred individuals in Australia,
predominantly young adults. It can cause significant morbidity from bowel ob-
struction, bowel perforation, perianal abscess or perianal fistula formation, or
chronic bowel inflammation. A significant proportion of patients with Crohn’s
disease develop irreversible bowel damage, damage which requires surgical resec-
tion of the affected bowel to relieve symptoms. Medical therapies used to treat
Crohn’s disease modify the host immune system and reduce bowel inflammation,
reducing symptoms of pain and diarrhoea, and possibly reducing progression to
irreversible bowel damage.
Medical therapies increase the risk of opportunistic infection, the risk of de-
veloping skin cancer or lymphoma, and carry a risk of drug induced effects such
as hepatitis or bone marrow suppression. These risks are likely to increase with
increasing strength of immunosuppression.
Therapy in Crohn’s disease needs to appropriately weigh risks and benefits for
individual patients. Accurate and objective prediction of likely outcome for pa-
tients with Crohn’s disease would aid in selection of appropriate therapy. This
body of work aimed to define objective, longitudinal tools to improve prediction
of outcome in Crohn’s disease.
There were two critical features which defined our approach in this work. The
first was the recording of objective clinical data in a longitudinal fashion. This
was achieved by designing a database with dated datafields, and endeavoring to
minimize subjectivity in datapoint recording. Further objective longitudinal data
were obtained through data linkage to laboratory databases. The second feature
was definition of an outcome which was reversible. This feature of outcome defi-
nition meant that analysis of longitudinal information was able to occur at many
timepoints in a patient’s disease course.
ii
A poor outcome was defined as the formation of a bowel stenosis, perforation
or fistula. Resolution of an outcome was defined as the passage of 2 years without
further observation of the outcome. Resolution could occur following surgery, or
passively with the passage of time. Perianal fistula formation was considered as
an independent outcome in a separate analysis.
A consistently low albumin level < 37 g L−1, a platelet count >370 x109/L, an
MCV < 86 fL and a neutrophil count >8.6 x109/L were identified to be associated
with subsequent bowel stenosis, fistula formation or perforation. Additionally, an
albumin level consistently < 38 g L−1 or a CRP consistently > 11 mgL−1 were
associated with subsequent perianal fistula formation. This information may lead
to enhanced outcome prediction in Crohn’s disease, and improved tailoring of ther-
apy for individual patients. These findings require validation in an external cohort.
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1.1.1. Biology of Crohn’s disease
Crohn’s disease is a chronic inflammatory condition which affects the human gas-
trointestinal tract. It was first described by Burrill Crohn et al. in 1932 as a chronic
inflammatory condition affecting the terminal ileum, characterized by stenosis and
fistula formation.(Crohn BB, Ginzburg L, and Oppenheimer GD 1932). The most
commonly affected segment of bowel remains the terminal ileum, however in its
current definition it may affect any part of the gastrointestinal tract, from the
mouth to the anus. It is characterized histologically by chronic transmural inflam-
mation of the gut wall, fissuring ulceration, transmural fibrosis, non-continuous
involvement of bowel segments, and granuloma formation.(Lennard-Jones 1989)
The aetiology of Crohn’s disease remains poorly understood.(Xavier and Podol-
sky 2007) It is hypothesized that an abberant chronic inflammatory state results
from interplay between a susceptible innate and adaptive immune system, the bar-
rier function of the intestinal wall and microbial gut flora.
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Studies into the genetics of Crohn’s disease have given insight into host de-
pendent factors that contribute to the pathogenesis of Crohn’s disease. The most
strongly associated genes are discussed briefly in this section. NOD2 is an intracel-
lular receptor protein expressed in immune and intestinal epithelial cells, especially
Paneth cells. It contributes to an innate immune response to bacterial antigens
through Nuclear Factor κβ (NF-κβ) signaling.(Ogura et al. 2001) Mutations in the
gene encoding this protein are associated with increased risk of developing Crohn’s
disease. ATG16L1 is a protein component of intracellular apparatus essential for
autophagy.(Mizushima et al. 2003) Mutations in the ATG16L1 gene predispose
to Crohn’s disease, implying autophagy plays a role in gut defence. IL23R is a
receptor protein expressed on the surface of immune cells, which increases cellular
responsiveness to the cytokine interleukin 23.(Parham et al. 2002) It plays a role
in the complex signalling between cells of the immune system that effects both an
innate and adaptive immune response against foreign antigens. One mutation in
the gene encoding IL23R confers protection against the development of Crohn’s
disease. JAK2 is a protein involved in the JAK/STAT signalling pathway that
communicates signals (including interferon-γ mediated signals) from receptors on
the cell surface to the nucleus, altering gene expression.(Watling et al. 1993) Mu-
tations in this gene are associated with uncontrolled cell proliferation, particularly
the myeloproliferative disorders polycythaemia rubra vera and essential thrombo-
cythaemia.(Baxter et al. 2005) They also are associated with the development of
Crohn’s disease, possibly due to an increase in intestinal permeability.(Prager et
al. 2012) PRDM1 encodes a DNA binding protein which regulates transcription of
the β-interferon gene and thus modulates immune function.(Keller and Maniatis
1991)
These genetic observations highlight the importance of the adaptive immune
system in maintaining a healthy gut free of chronic inflammation. The intestinal
microbial flora also play a role in perpetuating chronic Crohn’s inflammation in the
gut. Chronically inflamed mucosa represents a niche environment, with different
survival pressures in comparison to gut mucosa with normal barrier function. This
environment is rich in nutrients, but places pathogens in much closer proximity to
1. Literature Review 3
the host immune system. Some bacteria are able to adapt to this life. Adherent
Escherichia coli are present in ileal mucosa affected by Crohn’s disease in larger
numbers than in unaffected mucosa.(Darfeuille-Michaud et al. 2004) Adherent E.
coli from mucosa affected by Crohn’s disease activate NF-κβ, reducing production
of ATG16L1 and ATG5, and reducing effective autophagy.(H. T. T. Nguyen et al.
2014) Adherent E. coli bind to the mucosa of affected bowel by receptors for Car-
cinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6).(Barnich
et al. 2007) CEACAM6 expression on intestinal epithelial cells is upregulated by
IFN-γ and TNF-α, cytokines produced by an active host immune system. These
observations provide evidence that adherent E. coli have evolved an ability to
modulate the host immune system to their survival advantage.
1.1.2. Epidemiology and natural history of Crohn’s dis-
ease
The published prevalence of Crohn’s disease varies from 50-200 per 100,000 peo-
ple.(Gearry et al. 2006; Wilson et al. 2010; Loftus et al. 2007; Cosnes, Gower-
Rousseau, et al. 2011) The peak age of onset is between 20-40 years of age, and it
is more common in women than men by a factor of 1.3.(Gearry et al. 2006; Bern-
stein, Wajda, et al. 2006). Crohn’s disease is more common in smokers.(Persson,
Ahlbom, and Hellers 1990)
Most patients with Crohn’s disease have involvement of the ileum only, the colon
only, or of both the ileum and the colon. A small proportion of patients have iso-
lated involvement of the upper gastrointestinal system (oesophagus, stomach and
duodenum), or isolated orofacial involvement. Extent of disease remains stable
in the majority of patients, although a minority extend to ileocolonic involvement
from isolated colonic or ileal involvement, over their disease course.(Louis, Collard,
et al. 2001)
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The natural history of Crohn’s disease is varied. The condition is chronic, and
persists for most patients for decades. It is typically characterized by periods of
disease activity separated by periods of remission.(Munkholm et al. 1995) Up to
30% of patients have a penetrating bowel complication (bowel perforation or fis-
tula) or bowel stenosis at diagnosis.(Cosnes, S. Cattan, et al. 2002; Louis, Collard,
et al. 2001) This proportion increases to 40%-50% at five years. Perianal fistulae
are present in up to 20% of patients at diagnosis, and develop in a further 10%
over the next five years.(Schwartz et al. 2002; Cosnes, S. Cattan, et al. 2002) Pe-
rianal fistulae occur more commonly in patients with colonic involvement of their
luminal Crohn’s disease.(D. R. Williams et al. 1981; Rankin et al. 1979; Veloso
et al. 2001; Tang, Rawsthorne, and Bernstein 2006) Patients may also have symp-
tomatic diarrhoea and abdominal pain on a chronic basis.
In the current environment between 25% - 50% of patients with Crohn’s dis-
ease undergo bowel resection within 5 years of their diagnosis.(Ramadas et al.
2010) Malnutrition occurs in approximately 6% of patients with Crohn’s disease.
Fistulizing complications and bowel resection predispose to malnutrition.(G. C.
Nguyen, Munsell, and Harris 2008) For those that go under extensive resection
of their small bowel, there is a risk of short gut syndrome and consequent dehy-
dration, electrolyte disturbance and malnutrition.(Fleming, McGill, and Berkner
1977)
Extra-intestinal manifestations are immune mediated inflammatory conditions
which occur in patients with inflammatory bowel disease. They are: peripheral
arthropathy, iritis or uveitis, ankylosing spondylitis, primary sclerosing cholangi-
tis, erythema nodosum and pyoderma gangrenosum. They are more likely to be
present when there is active luminal inflammation, and occur in up to 26% of pa-
tients with Crohn’s disease.(Bernstein, Blanchard, et al. 2001; Rankin et al. 1979)
The most commonly reported extraintestinal manifestation is peripheral arthropa-
thy - a subjective symptom without an objective test to confirm diagnosis. When
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peripheral arthropathy is excluded, prevalence of the remaining extraintestinal
manifestations is around 6%.(Bernstein, Blanchard, et al. 2001).
1.2. Therapy in Crohn’s disease
Immunosuppressive therapy, exclusive enteral nutrition, antibiotic therapy and
surgery are currently used to treat Crohn’s disease. These treatments alter pa-
tient symptomatology, and some have been demonstrated to alter disease course.
Many of them have a significant adverse effect profile. The efficacy of currently
used treatments, and their side effect profiles, are outlined in this section.
1.2.1. Medical therapy
Medical therapy in Crohn’s disease is targeted at reducing inflammation, and pre-
venting complications of chronic inflammation. The majority of effective therapies
achieve this effect through modulation of the host immune system. Antibiotic
therapy is aimed at modifying the composition of enteric bacterial populations.
Exclusive enteral nutrition (EEN) is believed to reduce inflammation in Crohn’s
disease by either modifying the enteric bacterial population, and/or reducing the
permeability of the gut wall.(Day and Burgess 2013)
The first medical therapy used in the treatment of Crohn’s disease was Adreno-
corticotrophic Hormone (ACTH) in 1951.(Stanley, Rosenberg, and Cleroux 1951)
The effect of ACTH and cortisone in inducing clinical and biochemical remis-
sion was more clearly described over subsequent years.(Cooke and Fielding 1970)
The side effect profile of prolonged steroid use led to the use of steroid sparing im-
munosuppression for maintenance of remission.(Sandborn, Sutherland, et al. 1996;
Pearson, May, G. Fick, et al. 2000)
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Medical therapy for Crohn’s disease is considered in two contexts. Firstly, to
return a patient to health while acutely unwell with active Crohn’s inflammation -
remission induction. Secondly, to maintain health in a patient who is well without
active Crohn’s inflammation - maintenance of remission.(Dignass et al. 2010)
Steroid therapy
Corticosteroids are the medication most commonly used to induce remission in ac-
tive Crohn’s disease. They are associated with a relative risk of 1.99 of remission
induction when compared to placebo.(Benchimol et al. 2008) They reduce bowel
inflammation through a number of different mechanisms. They effect a reduction
in gene transcription of inflammatory cytokines including TNF-α and IL-6.(Yang
and Lichtenstein 2002) They also inhibit the effect of NFκβ on transcription of
non-steroid dependent inflammatory cytokines.(Yang and Lichtenstein 2002)
Thiopurines
Currently azathioprine and 6 mercaptopurine are commonly used in the manage-
ment of Crohn’s disease. These are prodrugs which are metabolized by the liver to
their active metabolites 6 thioguanine nucleotides (6TGN). 6TGN are thiopurine
analogues which interrupt purine synthesis, DNA and RNA synthesis, and ulti-
mately cell replication.(Sandborn, Sutherland, et al. 1996) Both drugs induce re-
mission of active luminal Crohn’s disease (OR=2.36, NNT=5), and are associated
with maintenance of remission (OR=2.32, NNT=6).(Sandborn, Sutherland, et al.
1996; Pearson, May, G. Fick, et al. 2000; Prefontaine et al. 2009) In a meta anal-
ysis, thiopurine use was associated with resolution of perianal fistulae.(Pearson,
May, G. H. Fick, et al. 1995) However, this effect has not been demonstrated as a
primary endpoint in a controlled trial.
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Methotrexate
Methotrexate is a folinic acid analogue and inhibits cellular metabolism. It has
been shown to induce remission (OR=1.95) and maintain remission (OR=1.67)
in luminal Crohn’s disease.(Feagan, Rochon, et al. 1995; Feagan, Fedorak, et al.
2000)
Anti TNF-α inhibition
TNF-α is an inflammatory cytokine which plays an important role in the process
which drives inflammation in Crohn’s disease. The anti TNF-α inhibitors inflix-
imab, adalimumab and certolizumab are manufactured antibodies with affinity for
TNF-α. They have been shown to be effective in inducing and maintaining re-
mission in Crohn’s disease.(J. F. Colombel et al. 2010; J.-F. Colombel et al. 2007;
Schreiber et al. 2007) Infliximab and adalimumab have been shown to aid healing
of perianal fistulae.(Present et al. 1999; J.-F. Colombel et al. 2007) In these two
trials closure of fistulae at 1 year occurred in 30-40% of patients in the treatment
arms compared with 10% in placebo arms.
Combination therapy using infliximab and a thiopurine medication has been
shown to be more effective than therapy with either medication alone at induc-
ing remission in patients with Crohn’s disease.(J. F. Colombel et al. 2010) This
is postulated to be due to either a synergistic immunosuppressive effect, or to a
reduction in formation of anti-infliximab antibodies in the presence of thiopurine
immunosuppression.
Anti-integrins
α4β1 and α4β7 integrins are molecules which regulate adherence and migration
of lymphocytes from the vascular system into brain and gut tissue respectively.
Natalizumab inhibits both of these molecules and has been shown to induce and
maintain remission in Crohn’s disease.(Sandborn, J. F. Colombel, et al. 2005;
Targan et al. 2007) Vedolizumab inhibits α4β7 integrin only and also induces and
maintains remission in Crohn’s disease.(Sandborn, Feagan, et al. 2013)
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Antibiotic therapy
Metronidazole has been shown to reduce postoperative recurrence of Crohn’s dis-
ease. (Rutgeerts et al. 1995) Antibiotics are used in conjunction with surgical
drainage to control perianal sepsis. Ciprofloxacin given for 12 weeks in combina-
tion with adalimumab increased the rate of healing of perianal fistulae.(Dewint
et al. 2014) This response lost clinical significance at 24 weeks.
Exclusive Enteral Nutrition
ENN is the provision of all nutritional requirements through a polymeric enteral
feed or an elemental (amino acid, glucose and fat) enteral feed, and the exclusion of
all other oral intake.(Day and Burgess 2013) EEN is effective at inducing remission
in paediatric Crohn’s disease.(Day and Burgess 2013; Johnson et al. 2006) In
partial enteral nutrition (PEN) a proportion of the nutritional requirements of the
patient is delivered via an enteral feeding tube, while a normal diet is taken orally.
Remission induction occurs with EEN and not PEN, suggesting that the efficacy
of the therapy depends on the removal of normal food from the diet.(Johnson et al.
2006)
1.2.2. Adverse effects of medical therapy
Infection
Use of steroid, thiopurine, or anti TNF-α therapy in Crohn’s disease is associ-
ated with an increased risk of infection.(Glazier et al. 2005; Lichtenstein, Fea-
gan, et al. 2012; Klein, Go, and Cunha 2001) The most commonly reported
infections are pneumonia, cellulitis, urinary tract infection and abscess forma-
tion.(Lichtenstein, Feagan, et al. 2012; Glazier et al. 2005) Absolute rates of sig-
nificant infection in patients with Crohn’s disease are of the order of 1-2 per 100
patient years.(Lichtenstein, Feagan, et al. 2012) Data regarding risk of infection
associated with immunosuppression in Crohn’s disease are confounded by higher
rates of immunosuppression use in sicker patients, who have increased risk of in-
fection independent of immunosuppression use.(Epple 2009)
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Opportunistic infections cause disease in immunocompromised hosts, while in
immunocompetent hosts they cause mild illness only. Anti TNF-α medications,
corticosteroids and thiopurines increase risk of opportunistic infection.(Lichtenstein,
Feagan, et al. 2012; Toruner et al. 2008) The most clinically relevant of these is
the reactivation of latent tuberculosis.(Raval et al. 2007) Reactivation of latent
tuberculosis in the setting of anti TNF-α therapy is associated with use of a sec-
ond immunosuppressive drug (methotrexate, azathioprine, prednisone).(Raval et
al. 2007)
In case studies anti TNF-αmedications have been reported to cause reactivation
of hepatitis B.(Esteve et al. 2004)
Hepatitis
Drug induced hepatitis can result from thiopurine, methotrexate or anti TNF-
α therapy.(Derijks et al. 2006; Feagan, Rochon, et al. 1995; Moum et al. 2007;
Menghini and Arora 2001) Harm from drug induced hepatitis may be reduced by
routine blood testing identifying asymptomatic biochemical hepatitis, leading to
cessation of therapy before hepatitis becomes clinically apparent. Thiopurine in-
duced hepatitis is associated with blood 6 methyl mercaptopurine (6MMP) levels
>5700 pmol/108 erythrocytes.(Dubinsky et al. 2000) Risk of significant thiopurine
associated hepatitis may also be minimized by monitoring thiopurine metabolites
and dose adjusting when indicated.
Cytopenia
Thiopurine, methotrexate and anti TNF-α use is associated with cytopenia.(Markowitz
2003; Salar et al. 2007; Lim, Gaffney, and D. G. I. Scott 2005) Blood count moni-
toring while on therapy may reduce the risk of severe cytopenia, and of consequent
bleeding and infective complications.
Infusion reaction or injection site reaction
6% of patients have a reaction to infused infliximab, and approximately 1% of these
are severe reactions characterized by hypotension, shortness of breath, tachycardia
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and facial flushing.(Cheifetz et al. 2003). Non-severe reactions can be managed by
slowing of infusion rate and administration of hydrocortisone. Injection site reac-
tions occur in 3% of patients using adalimumab or certolizumab.(J.-F. Colombel
et al. 2007; Schreiber et al. 2007)
Hypersensitivity reaction
Thiopurines carry a 2% risk of a hypersensitivity reaction after initiation.(Sandborn,
Sutherland, et al. 1996) This reaction is characterized by fever, arthralgia, myal-
gia, rash and raised inflammatory markers. It is typically symptomatically severe
and necessitates cessation of the drug. 2/3 of patients suffering a hypersensitivity
reaction to azathioprine are able to tolerate subsequent introduction of 6 mercap-
topurine.(Nagy et al. 2008)
Anti TNF-α induced Systemic Lupus Erythmatosis (SLE)
Administration of anti TNF-α medication stimulates cell lysis and exposure of
DNA to the host immune system. An immune response to these antigens can
occur, leading to the development of drug induced SLE.(Vermeire, Noman, et
al. 2003) Incidence of drug induced lupus is of the order of 0.2% of treated pa-
tients.(De Bandt et al. 2005) The condition resolves with cessation of the drug.
Skin cancer
In Australia the risk of non-melanoma skin cancer is of the order of 1170 per
100,000 person years.(Staples et al. 2006) For those less than 40 the risk is 210
per 100,000 person years, while for those of over the age of 70 the risk is 7305
per 100,000 person years. (Staples et al. 2006) Incidence of non-melanoma skin
cancer is increased by a factor of 6 in patients taking thiopurines.(Peyrin-Biroulet
et al. 2011) There are no clear data to suggest that anti TNF-α medications
are associated with non-melanoma skin cancer.(Lichtenstein, Feagan, et al. 2012)
Melanoma appears to be more common in patients with inflammatory bowel dis-
ease. There has been no association between immunosuppressive medication use
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and melanoma. (Singh et al. 2014) There are conflicting data regarding the risk of
melanoma associated with the use of anti TNF-α medications.(Singh et al. 2014;
Long et al. 2012)
Lymphoma
Incidence of Non-Hodgkin’s Lymphoma (NHL) in the general population increases
from 1 per 10,000 person years for those aged less than 40, to 9 per 10,000 person
years for those aged over 80.(Kandiel et al. 2005). Risk of NHL is probably not
increased in patients with Crohn’s disease.(Lewis et al. 2001) Thiopurine use in-
creases the risk by a factor of 4, and combination thiopurine and anti TNF-α use
increases the risk by a factor of 6.(Siegel et al. 2009; Kandiel et al. 2005)
There have been 36 reports of hepatosplenic T-cell lymphoma in patients taking
either thiopurine monotherapy or combined anti TNF-α and thiopurine immuno-
suppression for inflammatory bowel disease.(Kotlyar et al. 2011) This is a cancer
which is often fatal and has predominantly affected men under the age of 35. It is
difficult to assess incidence from what are a collection of reported adverse events,
however for men under the age of 35 it has been estimated to be 1/7404 for those
taking thiopurine monotherapy, and 1/3534 for those taking an anti TNF-α agent
and a thiopurine in combination.(Kotlyar et al. 2011)
Progressive Multifocal Leukoencephalopathy
Progressive Multifocal Leukoencephalopathy is a progressive neurological condi-
tion. It is an opportunistic infection caused by reactivation of latent JC (John
Cunningham) polyomavirus, and has been observed in 2/1000 patients treated
with the anti-integrin antibody natalizumab in post marketing analysis. 20%
of those affected die, and half of survivors are left with severe neurological dis-
ability.(Bloomgren et al. 2012) Vedolizumab is not associated with this condi-
tion.(Sandborn, Feagan, et al. 2013)
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1.2.3. Surgical therapy
Surgery plays a major role in the management of Crohn’s disease. It can be per-
formed to relieve chronic symptoms which are refractory to medical therapy. For
example, resection of a symptomatic stenosis, or colectomy in colitis refractory
to medical therapy. It also is considered early in the course of disease, with the
goal of providing a prolonged period of good health, without medical therapy and
its associated side effects.(Latella, Caprilli, and Travis 2011) Surgery plays an im-
portant role in the management of perianal fistulae. Finally, Crohn’s disease can
lead to acute severe complications which require emergency surgery, such as acute
bowel perforation or obstruction. However, the majority of surgery performed in
Crohn’s disease is elective.(Siassi et al. 2007)
Small bowel or colonic resection
Bowel resection in Crohn’s disease removes diseased segments of bowel, and is the
operation of choice for ileal and colonic Crohn’s disease. Bowel segments may be-
come severely damaged from chronic inflammation, with little likelihood of medical
therapy repairing the functionality of the damaged tissue and relieving symptoms.
Symptomatic bowel stenosis, chronic enterocutaneous fistulae, enterovesical fistu-
lae or enterovaginal fistulae are examples of such situations.(T. Yamamoto and
Watanabe 2014) Chronic inflammatory intra-abdominal or retroperitoneal collec-
tions, which remain in communication with an involved segment of bowel, cause
chronic inflammation and pain. They are considered an indication for resection of
the involved bowel. Finally, resection of the colon is performed in chronic refrac-
tory colitis.
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Surgery in Crohn’s disease aims to remove complications of chronic inflamma-
tion (stricture, fistula) without removing all diseased bowel.(Alexander-Williams
and Haynes 1987) This approach acknowledges that extensive removal of bowel
does not cure Crohn’s disease, and increases risk of short gut syndrome.
Colonic resection
Surgical options for colonic Crohn’s disease include proctocolectomy with perma-
nent end ileostomy formation, colectomy and ileorectal anastamosis, or limited
colonic resection. Disease recurrence in the rectum is a common outcome after ile-
orectal anastamosis. However, severe symptoms leading to permanent ileostomy
formation were observed to occur in 14% of patients in the 10 years following
reanastamosis.(P. Cattan et al. 2002) Ileal pouch-anal anastamosis is associated
with a significant rate of fistulizing complications and is usually avoided in Crohn’s
disease.(T. Yamamoto and Watanabe 2014)
Stricturoplasty
In diffuse jejunal disease, or in cases of multiple previous bowel resections, there
is appreciable risk of short gut syndrome with further bowel resection. Stric-
turoplasty is considered a valid bowel preserving operation to relieve obstructive
symptoms. In one series the rate of recurrent stricture at the site of stricturoplasty
was of the order of 20-30% at 6 years.(Dietz et al. 2002)
Surgical management of perianal fistulae
Perianal fistulae expose perianal tissues to faecal contamination, and are a source
of recurrent localized sepsis. Surgical management of perianal fistulae, performed
in combination with medical therapy, increase the likelihood of their resolution,
and reduce the severity of symptoms suffered by patients.
Prompt surgical drainage of perianal fistulae is required when they occur. In-
sertion of a non-cutting seton provides drainage and reduces incidence of recurrent
abscess formation.(Gecse et al. 2013) There is no consensus on optimal timing for
removal of setons in perianal Crohn’s fistulae. Risk of recurrent abscess increases
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with removal of the seton, however healing of the fistula will not occur until the
seton is removed.
Low perianal fistulae which do not involve the sphincter muscle complex are
amenable to laying open without risk of loss of continence. Healing of fistulae with
this procedure are of the order of 80%.(H. J. Scott and Northover 1996)
There is no clear evidence regarding the efficacy of rectal flap advancement for
the treatment of high perianal fistulae in Crohn’s disease.(Soltani and Kaiser 2010)
Observational studies cite wide ranges of success of this procedure (33-92%). It is
accepted to be less successful for rectovaginal fistulae.(Soltani and Kaiser 2010)
Formation of a loop ileostomy diverts the faecal stream from the colon and is
performed to increase the likelihood of healing of severe perianal Crohn’s disease.
The ostomy may be reversed after a period of time, although recurrent disease
precludes reversal for the majority of these patients.(T. Yamamoto, Allan, and
M. R. Keighley 2000)
In cases of severe perianal Crohn’s disease proctectomy and permanent ileostomy
relieves symptoms of chronic debilitating perianal Crohn’s disease.(Mueller et al.
2007)
1.2.4. Adverse effects of surgery
Surgery entails risk of complications such as anastomotic breakdown, intra-abdominal
sepsis, formation of enterocutaneous fistulae through the surgical wound, wound
infection, pulmonary embolism or pneumonia.(D. T. Yamamoto, Allan, and M. R. B.
Keighley 2000) The risk varies depending on a number of factors, including the
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surgical procedure being performed, whether it is an acute or elective procedure,
steroid use leading up to the operation, patient age, nutritional status and the pres-
ence of obesity. The risk of a significant complication is in the order of 13%.(D. T.
Yamamoto, Allan, and M. R. B. Keighley 2000)
1.3. Decision making in the management of
Crohn’s disease
The management of Crohn’s disease is a long term undertaking. Physicians ad-
vise patients to take therapies with a significant side effect profile for many years,
with the expectation of reducing current symptoms and reducing the risk of fu-
ture complications of their disease. This complex decision making is dependent
on assessment of risk of adverse outcome in the absence of therapy, the risks of
therapy, and of improvement in outcome attributable to the chosen therapy.
The management of patients with Crohn’s disease represents a significant cost
to healthcare organizations.(Bernstein, Longobardi, et al. 2012) The largest direct
costs are hospital admission and anti TNF-α prescription. In addition to the direct
cost of providing treatment, indirect costs due to loss of work productivity are also
incurred. Anti TNF-α medications have significantly increased the cost of therapy
in Crohn’s disease. In Australia the annual cost of anti TNF-α therapy is of the
order of $AU30,000 - $AU40,000 per patient per year.(Australian Government De-
partment of Health 2014a; Australian Government Department of Health 2014b).
This expense is likely to be offset by direct and indirect savings due to reduced
hospital admissions and increased work productivity.(Bernstein, Longobardi, et al.
2012)
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The provision of all expensive pharmaceuticals available today to those who
would benefit from them would be likely to bankrupt any public health system.
Expensive therapies such as anti TNF-α medications currently need to be ratio-
nally allocated by a public health system if their use is to be sustainable. In today’s
environment, cost has some influence over choice of therapy for individual patients.
1.3.1. Utility of outcome prediction
Outcome prediction in Crohn’s disease allows physicians to tailor an individual
patient’s therapy based on their likely disease course. A high likelihood of poor
outcome will increase the potential benefit of aggressive therapy, and make it more
attractive despite its side effect profile.
1.4. Poor outcome in Crohn’s disease
1.4.1. Outcome definition
The model of Crohn’s disease on which current treatment strategy is based is
of chronic bowel inflammation leading to bowel damage, and symptoms resulting
from either tissue damage or from inflammation itself.(Cosnes, S. Cattan, et al.
2002) It may take many years for evidence of tissue damage to become appar-
ent.(Thia et al. 2010; Cosnes, S. Cattan, et al. 2002) The advancement of thera-
peutic options to manage Crohn’s disease has depended on timely assessment of
efficacy of novel therapies. Rather than waiting many years for development of tis-
sue damage, efficacy has been measured by change in disease activity attributable
to the therapy being tested.(for example; J. F. Colombel et al. 2010)
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Degree of bowel inflammation, or severity of symptoms attributable to Crohn’s
disease, are both used as measures of disease activity. The gold standard measure-
ment of bowel inflammation is considered to be endoscopic assessment. However,
the invasive nature of colonoscopy means that clinical symptoms, or non-invasive
biological markers, are often used to measure disease activity. Validated measures
of short-term outcome include the Simple Endoscopic Score in Crohn’s Disease
(SES-CD, see table 1), mucosal healing (defined as the absence of ulceration at
ileocolonoscopy), the Crohn’s Disease Activity Index (CDAI, see table 2), or biolog-
ical markers such as C-Reactive Protein (CRP) and faecal calprotectin. (Daperno
et al. 2004; De Cruz et al. 2013; Best et al. 1976; Schoepfer, Beglinger, et al. 2010)
The most commonly used clinical measurement of disease activity in clinical trials
is the CDAI. This index sums scores of bowel frequency, patient reported sever-
ity of abdominal pain, general wellbeing, presence of perianal disease, presence
of extraintestinal manifestations of inflammatory bowel disease (arthralgia, iritis,
erythema nodosum, apthous ulceration, pyoderma gangrenosum), fever, use of an-
tidiarrhoeal medications, haematocrit and weight. Disease activity - as measured
by CDAI, endoscopic assessment or with biological markers - is often used as an
endpoint in pharmacological trials, as a measure of response to immunomodulatory
therapy.(for example; J. F. Colombel et al. 2010) These are the outcome variables
which have been used to demonstrate the efficacy of the medical treatments listed
in section 1.2.1.
Chronic disease activity is associated with symptoms which reduce quality of
life, and is considered to increase the risk of surgery.(Lichtenstein, Yan, et al. 2004)
Of all measures of disease activity, absence of mucosal healing is the measure that
has been most strongly predictive of surgery in Crohn’s disease.(Schnitzler et al.
2009)
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1.4.2. Definition of long term outcome
Crohn’s disease is a chronic condition. Descriptions of long term outcome allow
clinicians to inform newly diagnosed patients of how Crohn’s disease may affect
their life. Validated measures of disease activity are not measures of long term
outcome. Long term outcome is typically measured by major events in the natural
history of Crohn’s disease. Examples used in longitudinal studies include bowel
resection, a requirement for long term steroid use and a requirement for immuno-
suppressive therapy.(Ramadas et al. 2010; Solberg et al. 2007)
Clear definitions of poor long term outcome allow observation of occurrence
of such an outcome in a cohort, and also observation of which patients tend to
progress to the outcome. This information could be used to stratify patients with
Crohn’s disease into those likely to benefit from aggressive therapy, and those
whose disease course may not warrant the side effect profile.
In the literature there is variability in the definition of a poor long term out-
come in Crohn’s disease.(Beaugerie and Sokol 2012) The term disabling disease
was coined by Beaugerie et al. to describe a poor clinical course.(Beaugerie, Sek-
sik, et al. 2006) It was defined as one or more of the following: administration
of two or more courses of steroids, long term steroid use, hospitalization for a
disease flare, presence of disabling chronic symptoms (cumulative time of more
than 12 months of disabling symptoms (diarrhea with nocturnal and/or urgent
stools, intense abdominal pain because of intestinal obstruction, fever, fatigue at-
tributable to the disease, joint pain, painful uveitis or pyoderma gangrenosum), a
need for immunosuppressive therapy, undergoing an intestinal resection, or under-
going a perianal surgical procedure. This definition was also used in a validation
study.(Loly, Belaiche, and Louis 2008) In the study by Loly et al. a second anal-
ysis was performed which defined severe Crohn’s disease as one or more of the
following: the development of complex perianal disease, any colonic resection, two
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or more ileal resections, a single resection of 50cm or more of small bowel, or cre-
ation of a permanent stoma.
Pariente et al. have proposed an objective scoring system, the Lémann Score,
to describe outcome in Crohn’s disease.(Pariente, Cosnes, et al. 2011; Pariente,
Mary, et al. 2015, see table 5). This score is being developed with the goal of
standardizing the measurement of poor outcome in Crohn’s disease. It assigns a
score to represent tissue damage at each of 4 bowel segments: the upper gastroin-
testinal tract, the small bowel, the colon, and the perineum/anus. Tissue damage
may be measured on clinical examination, at ileocolonoscopy, at oesophagogas-
troduodenoscopy (OGD), on radiological imaging, at surgery or on examination
of surgical specimens. The score is cumulative, meaning once tissue damage has
been observed at one segment it is never considered normal again.
1.4.3. Difficulties in long term outcome definition
Many of the outcome variables used to define poor outcome in the literature to
date lack objectivity. Measures such as a need for immunotherapy, or hospital-
ization for a disease flare are subject to variable physician threshold. Symptoms
such as fatigue, joint pain or abdominal pain are by nature subjective and will
be reported variably by patients. A lack of objectivity means that results from
studies using these outcome definitions are difficult to compare to each other. Ad-
ditionally, it is difficult for physicians to determine how such results will translate
to their own patient population.
1.4.4. Predictors of currently defined poor outcome
Three clinical variables have been identified as predictive of disabling disease as
defined by Beaugerie et al: Steroid use at diagnosis, age below 40 years at diag-
nosis and perianal disease at diagnosis.(Beaugerie, Seksik, et al. 2006) Stricturing
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disease at diagnosis and weight loss greater than 5kg at diagnosis predict the de-
velopment of severe Crohn’s disease as defined by Loly et al. Currently these are
the variables which are taken into consideration by most physicians when making
decisions regarding therapy for patients with Crohn’s disease.
Further variables have been noted to correlate with poor outcome in Crohn’s
disease. NOD2 genotype is associated with the development of stenotic or pen-
etrating complications(Adler et al. 2011), active smoking with penetrating com-
plications (Louis, Michel, et al. 2003), and anti Saccaromyces cerevisiae antibody




2.1.1. Measurement of outcome
Our initial literature review covered prediction of outcome in Crohn’s disease. Ini-
tial consideration focused on identifying novel predictors of outcome in Crohn’s
disease, or significant unidentified interactions between recognized predictors of
outcome. Genome wide association studies (GWAS) have identified 140 single nu-
cleotide polymorphisms (SNPs) associated with Crohn’s disease, when comparing
cases with non-affected controls.(Jostins et al. 2012; Hugot et al. 2001; Franke
et al. 2010; Barrett et al. 2008) An interaction between ATG16L1 and smoking
increasing risk of Crohn’s disease has been reported,(Fowler et al. 2008) and other
interactions are likely to exist. A significant proportion of the RBWH Crohn’s
cohort has been genotyped, and so exploration of the interaction between genetic
and environmental variables and outcome was strongly considered.
Having identified genetic variants associated with incidence of Crohn’s disease,
the literature has progressed to explore their relationship with Crohn’s phenotype.
NOD2 variants have been associated with ileal disease location, earlier onset of
disease, penetrating and stricturing phenotype (Cleynen et al. 2012; Weersma et
al. 2009; Economou et al. 2004; Jung et al. 2012), while ATG16L1 variants have
been associated with ileal location of disease.(Fowler et al. 2008) IL23R genotype
and JAK2 genotype are associated with colonic location of disease.(Cleynen et al.
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2012) JAK2 is associated with stenosing phenotype, and PRDM1, NOD2 variants
and IL23R are associated with penetrating phenotype.(Cleynen et al. 2012) The
number of patients in our cohort (~300) meant that genotype/phenotype analysis
was not likely to be a successful strategy due to lack of statistical power and was
not pursued further.
During this literature review it became apparent that definitions used to de-
scribe outcome in Crohn’s disease vary, and additionally often describe outcome
using subjective variables.(Ramadas et al. 2010; Beaugerie, Seksik, et al. 2006;
Loly, Belaiche, and Louis 2008) To illustrate this point, an outcome variable re-
peatedly used in the Crohn’s literature is a requirement for surgery. Surgery is
performed for patients with Crohn’s disease based on physician and surgeon opin-
ion of its benefit, and patient agreement to undergo the proposed procedure. In
some cases this is a clear cut decision (for example in acute peritonitis from bowel
perforation), however in other situations opinion between clinicians varies (for
example early ileocolic resection for isolated inflammatory terminal ileal Crohn’s
disease).(Latella, Caprilli, and Travis 2011) Additionally, patients may refuse to
undergo surgery. Although a major event in a patient’s disease course, the per-
formance of surgery per se. is unlikely to represent a reproducible and objective
measure of disease progression. In support of this observation, there have been sig-
nificant differences in rates of surgery observed across centres in Europe.(Wolters,
M. G. Russel, et al. 2006)
The International Program to develop New Indexes in Crohn’s disease (IPNIC)
is developing a system to objectively classify bowel damage in Crohn’s disease - the
Lémann score.(Pariente, Cosnes, et al. 2011; Pariente, Mary, et al. 2015) It derives
a score calculated from perforation, stricture formation or performance of surgery,
for each of four segments of the human gastrointestinal tract - the colon, the small
bowel, the upper gastrointestinal tract, and the anus/perianal region. (See ta-
ble 5). The pertinent features of the Lémann score are that it is reproducible,
objective, and measures bowel damage irrespective of whether or not surgery is
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performed. This score shows promise in providing an objective and reproducible
measure of outcome in Crohn’s disease.
2.1.2. Longitudinal predictor variables
Our cohort of Crohn’s disease patients have had a large number of objective tests
performed on them as part of their clinical management. As far as we are aware,
these type of data have not been used significantly in the Crohn’s disease literature
to date.(Vermeire, Van Assche, and Rutgeerts 2006) Laboratory data in particular
are measured in a serial fashion, and represent an opportunity to consider predic-
tion of outcome at many different timepoints in a patient’s disease course. We have
recognized these data as a silo of objective longitudinal information describing our
patients, and have incorporated them into our analysis.
2.2. Statement of hypotheses
1. That collection of objective, longitudinal clinical data will allow further in-
sight into the natural history of Crohn’s disease, beyond that provided by
traditional phenotyping by Montreal or Vienna classification systems.
2. That a set of objective, reproducible and clinically relevant measures of poor
outcome in Crohn’s disease may be defined for use in longitudinal analyses.
3. That objective variables, measurable in a longitudinal fashion throughout a
patient’s disease course, will aid in predicting progression to a poor outcome
in Crohn’s disease.
3. Methodology
3.1. Definition of poor outcome
We have defined poor outcome in Crohn’s disease for use in longitudinal analysis
(Table 3.1). This definition has been carefully considered to represent measurable,
objective tissue damage with significant symptomatic consequences. It has also
been defined to allow multiple occurrences of an endpoint during a patient’s dis-
ease course.
This is a noteworthy point of difference from the Montreal classification of
disease behaviour and the Lémann score. (Satsangi et al. 2006; Pariente, Mary,
et al. 2015) Both of these scores consider disease complication or outcome in a
cumulative fashion, and therefore a patient may never reduce their score over time.
This means that both of these systems by definition will observe worsening disease
over time. They are also less able to analyze further disease progression following
assignment of a high score. To illustrate this point consider possible disease courses
following an ileocolic resection for terminal ileal stricture or perforation. One
patient may have 3 further anastomotic resections over the subsequent 10 years for
recurrent stricture, and a second patient may have no further complication. The
Montreal behaviour classification does not distinguish between these two patients
despite their markedly different clinical course. We feel that it is crucial that our
outcome measure is able to distinguish between such patients. Our approach to
achieving this is to define outcome in a way that allows resolution of an observed
outcome.
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3.2. Data collection
3.2.1. Datapoint selection
Objective data were entered into a database designed to record a longitudinal de-
scription of disease course for patients with Crohn’s disease. Data was obtained
from the clinical record, and from the RBWH phenotypic research database. Dat-
apoints were selected according to the following criteria:
1. Include previously described predictors of poor outcome in Crohn’s disease:
steroid use at diagnosis, perianal disease at diagnosis, age at diagnosis, stric-
turing behaviour at diagnosis, weight loss at diagnosis and platelet count at
diagnosis. (Loly, Belaiche, and Louis 2008; Beaugerie, Seksik, et al. 2006)
2. Include longitudinal laboratory data.
3. Include outcome variables as described in table 3.1: radiology results, en-
doscopy results, operative surgical and histological findings, clinical observa-
tion of enterocutaneous fistulae, findings at examination under anaesthetic
(EUA), and perianal examination findings.
4. Include variables considered to have an influence over outcome: medication
use, smoking.
A critical aspect of how these data have been coded is their temporal nature.
For example, the use of thiopurine immunosuppression has not been recorded as
“yes, >6 months” or “no”. Instead this information has been coded using dat-
apoints “date start”, “date stop”, “dose”,“cessation reason” for each thiopurine
used. This allows detailed temporal association of recorded variables with out-
come.
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A coding system for selected datapoints was defined and reviewed with Graham
Radford-Smith. This system was then used to code a pilot group of 15 patients,
which identified datapoint omissions and coding inconsistencies. These were ad-
dressed and optimized before embarking on coding the entire cohort. The attached
document Longitudinal Crohn’s Database Coding Manual describes in detail the
datapoints and how they have been coded.
3.2.2. Included variables
Table 3.2 lists the variables included in this analysis.
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Objective endpoint Modality of observation Criteria
Stricture development Imaging Bowel lumen narrowing and
proximal dilatation ≥ 2.5cm
Surgery Stricture identified by surgeon
or pathologist
Endoscopy Stricture identified by endoscopist,
unable to be traversed
Perforation Imaging Extraluminal collection or
free air in the abdomen or phlegmon
Surgery Extraluminal collection or phlegmon
or faecal contamination of abdomen
Fistula Imaging Radiologically evident fistula
Surgery Surgical evidence of fistula
Clinical examination Evidence of entero-cutaneous fistula or
entero-vesical fistula
Perianal disease Imaging Radiologically evident perianal fistula
Surgery Evidence of perianal fistula
Clinical exam Evidence of perianal fistula
Table 3.1
Definition of poor outcome in Crohn’s disease.
1: Development of a single endpoint represents a poor outcome.
2: Timing of endpoint development is at its earliest detection.
3: Endpoints which result from surgery or endoscopic procedures are excluded.
4: Endpoints are considered present until they are resolved. Resolution is
defined as the passage of two years without further observation of the endpoint.
Endpoints may resolve with surgery, or passively.
5: Endpoints which occur before resolution of a previous endpoint are
considered part of that endpoint.
6: Resolution of an endpoint will return a patient to the status of “no endpoint
met”.
7: Intra-abdominal and perianal endpoints are considered separately.
Imaging includes MR enterography, CT enterography, USS, barium meal,
barium enema, anal ultrasound.
Endoscopy includes ileocolonoscopy, flexible sigmoidoscopy, OGD, enteroscopy,
capsule endoscopy.
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Predictor Variables Outcome Variables
Laboratory Values Endoscopy Data ?
Haemoglobin Colonoscopy
White cell count Flexible sigmoidoscopy
Neutrophil count OGD
Platelet count Capsule endoscopy
CRP Enteroscopy
ESR
Ferritin Radiology Data ?
Transferrin saturation MR enterography


















Medication Use Intravenous steroid use













? Data collected from endoscopy procedures, imaging, surgery, and clinical
examination are used to identify luminal or perianal fistulae, perforation,
intra-abdominal or perianal abscess formation or bowel stenosis.
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3.3. Cohort selection
3.3.1. Royal Brisbane and Women’s Hospital Crohn’s dis-
ease cohort
The RBWH IBD unit came into being with the arrival of Graham Radford-Smith
to the hospital in the early 1990’s. Before this time patients with IBD were
managed by many gastroenterologists in the hospital. Graham focused his clinical
work in the field of IBD and has maintained an active research program. Under his
leadership an inflammatory bowel disease unit has evolved which provides all IBD
care at RBWH. He and the unit have been recruiting patients with inflammatory
bowel disease into the RBWH and QIMR Berghofer research programme from
1994.
The cohort of patients with Crohn’s disease which are studied in this thesis are
those that have been treated at the RBWH IBD unit, and have been consented
for the research programme by Graham and his team over this time.
3.3.2. Inclusion and exclusion criteria
To be included in the cohort patients need to meet the following inclusion and
exclusion criteria:
1. Inclusion Criteria
(a) Meet the Lennard-Jones criteria for a diagnosis of Crohn’s disease
(Lennard-Jones 1989) - see table 3.
(b) Have a minimum of five years of follow-up in the clinical record.
2. Exclusion Criteria
(a) Diagnosis before 1994.
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(b) Lack of longitudinal laboratory data.
There is no clear consensus regarding diagnostic criteria for Crohn’s disease.
The most commonly cited diagnostic criteria are the Lennard-Jones criteria. (Lennard-
Jones 1989) These criteria depend on demonstrating evidence of transmural disease
involvement (submucosal fibrosis, submucosal ulceration, evidence of perforation,
fistula or macroscopic fibrosis). Because of this a diagnosis is often not formally
met until surgery has been performed and a macroscopic surgical specimen is ob-
tained for analysis. This concern has been acknowledged by the European Crohn’s
and Colitis Organization (ECCO) who formed a consensus statement which covers
the diagnosis of Crohn’s disease. (Van Assche et al. 2010) The ECCO diagnostic
criteria are less strict, however are not clearly defined. This is illustrated by the
following two quotes from this document. (Figures 3.1, 3.2)
A single gold standard for the diagnosis of CD is not available. The
diagnosis is confirmed by clinical evaluation and a combination of en-
doscopic, histological, radiological, and/or biochemical investigations.
Genetic testing is currently not recommended for routine diagnosis or
management of CD. [EL5, RG D].
Figure 3.1
Consensus statement 2B from ECCO consensus guidelines, pg 12.
(Van Assche et al. 2010)
The current view is that the diagnosis is established by a non strictly
defined combination of clinical presentation, endoscopic appearance,
radiology, histology, surgical findings and, more recently, serology. This
still results in diagnostic obstacles.
Figure 3.2
Taken from text of ECCO consensus guidelines, pg 12.
(Van Assche et al. 2010)
Therefore diagnostic criteria for this cohort were consistent with the Lennard-
Jones criteria. However, patients who did not undergo surgery, and therefore
did not have a transmural surgical specimen for examination, were not required
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to demonstrate evidence of transmural bowel involvement. For these patients
evidence of chronic mucosal bowel inflammation in a typical distribution (ileal
only, or non-continuous colonic) was considered adequate for diagnosis.
3.4. Data collection
3.4.1. Database design
The database is designed in SQLite. It is in a simple table format, with all data-
points on one row and one row per patient. Data analysis was performed with the
data in a relational format. An algorithm (written in R) converts the data into a
relational format for subsequent analysis.(See coding definition 3)
3.4.2. Data linkage
All patients who have consented to take part in the RBWH IBD research pro-
gramme, or are clinical patients treated by the RBWH IBD department, are as-
signed a unique identifying number. This number identifies all data attributable
to that patient on a clinical and phenotypic database. Genetic and serological
analysis performed on patient blood and serum at the QIMR Berghofer is also
recorded against this number. Data linkage between patients and genetic data
has been performed using this identification number.
The Queensland public health system does not maintain a single statewide
medical record number, and individual patients may have multiple different iden-
tification numbers which vary by attended public hospital. For this reason data
linkage to laboratory data stored on the AUSLAB and PARIS databases has been
made using identifying data which were common between databases: first-name
/ last-name / date of birth / sex. The same matching data was used to link our
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cohort to data from S&N (Sullivan and Nicoloides) and QML (Queensland Medi-
cal Laboratories) databases. The pertinent features of the databases to which we
have linked data are outlined below.
1. AUSLAB database
(a) Queensland wide, public health system laboratory data
(b) Tests ordered on our patients at other public hospitals in Queensland
captured
(c) Electronic recording of results began in 1999
2. PARIS database
(a) Greater Brisbane region, public health system laboratory data
(b) Tests ordered on our patients at other public hospitals in Greater Bris-
bane captured
(c) Electronic recording of results 1985 - 1998
3. S&N database
(a) A private laboratory service
(b) Electronic record began in 2001
4. QML database
(a) A private laboratory service
(b) Electronic record began in 1995
5. QIMR Berghofer IBD research group genetic database
(a) Matched to Crohn’s disease cohort by unique identifying number
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3.5. Statistical analysis
3.5.1. Cohort size
Our cohort size was determined by the number of patients who met our inclu-
sion criteria, and is currently 302 patients with a median of 10 years of follow-up.
A calculation of statistical power would not have altered our approach beyond
deciding whether or not it was likely to be worthwhile collecting the data and per-
forming the analysis, as there was no capacity to increase the size of the cohort.
We estimated that the size of the cohort would allow identification of significant
association between predictor and outcome variables using Cox regression, includ-
ing up to 10 predictive variables in a final model.
The power of this cohort to detect association between predictor and outcome
variables is dependent on the frequency of occurrence of outcome variables, and
the distribution of predictor variable status amongst patients. We estimated the
frequency of outcome over 10 years to be in the order of 30-50%, based on pub-
lished figures for the development of penetrating or stricturing complications of
Crohn’s disease.(Thia et al. 2010)
3.5.2. Statistical approach
Recording longitudinal data allowed temporal association of predictor and outcome
variables. Correlation between predictor variables and outcome was performed al-
lowing study subjects to experience multiple outcome events as described in the
method by Prentice et al.(Prentice, B. J. Williams, and Peterson 1981) (see fig-
ure 3.3). This method analyzes predictor variables as a function of time to event
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Figure 3.3
Strategy for analysis of longitudinal data
from date of diagnosis or from resolution of the immediately preceding outcome,
whichever was the more recent.
Temporal laboratory variables used as predictive variables were analyzed in re-
lation to the outcome variable using Cox regression analysis. For each variable a
variation on area under the curve was used to convert multiple values into a single
representative value. (see code definition .1.5)
In the final model continuous variables were converted to dichotomous cate-
gorical variables, which we consider are more easily interpretable by clinicians.
This was performed using an automated algorithm which maximized association
between a predictor variable and outcome depending on the cutoff used. This was
performed using the log-rank statistic and univariate Cox regression. (see code
definition 15)
4. Description of Cohort and Objective
Data Collected
Review of records at the Royal Brisbane and Women’s Hospital IBD unit and at
the QIMR Berghofer identified 360 patients diagnosed with Crohn’s disease after
the 1st January 1994 and before 31st March 2008. 58 of these had less than 5 years
of clinical follow-up and 11 had inadequate laboratory data available for analy-
sis.(table 4.1).
Total 360
<5 years follow-up 58




The method of data recording for each event is demonstrated by figure 4.2,
which shows as an example how a single colonoscopy was recorded.
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Example of coding for a colonoscopy
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Summary Box
What is already known:
Outcome prediction in Crohn’s disease
helps tailor therapy to individual pa-
tients. The following clinical features
predict worse outcome and should lower
threshold for increasing intensity of treat-
ment.
• Age < 16 years at diagnosis
• Receiving steroids for first disease
flare
• Presence of perianal disease at diag-
nosis
What are the new findings:
Consistently low albumin < 38g L−1, high
platelet count > 370x109/L, low mean cell
volume < 86 fL and high neutrophil count
> 8.7 x109/L are associated with subse-
quent bowel stenosis, fistulization or perfo-
ration.
How might it impact on clinical
practice in the foreseeable future:
If validated in other cohorts, these labo-
ratory variables could be used in addition
to recognized clinical features to enhance
prediction of poor outcome in Crohn’s dis-
ease, and to tailor therapy more accurately
to those who are most likely to benefit from
it.
5.3. Abstract
Objective: To study the correlation between longitudinal laboratory testing and
subsequent bowel stenosis, bowel perforation or intra-abdominal fistula formation
in patients with Crohn’s disease.
Design: Patients diagnosed at a tertiary referral centre with Crohn’s disease be-
tween 1st January 1994 and 31st March 2008, with more than five years of follow-up,
were analyzed. An objective poor outcome (OPO) was defined as the development
of a fistula, bowel stenosis or bowel perforation. Laboratory data were recorded
when patients were well, prior to each OPO. Cox regression was used to analyze
the association between OPO development and; C reactive protein, erythrocyte
sedimentation rate, platelet count, haemoglobin level, mean cell volume, white
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blood cell count, neutrophil count, albumin, alanine transaminase, vitamin D,
vitamin B12, folate, faecal calprotectin, serum iron, transferrin saturation and
ferritin level.
Results: In 291 patients observed over a median of 10.49 years, blood testing was
performed a median of 4.72 (IQR 3.07-7.12) times per year, over a median of 4.79
(IQR 2.84–7.76) years prior to each OPO. 183 OPOs (116 independent stenoses,
14 independent perforations, 15 independent fistulae and 38 combination events)
were observed. After multivariate analysis an albumin level consistently < 37
g L−1 (HR 4.41, p<0.001), a platelet count > 370 x109/L (HR 2.22, p=0.037), an
MCV < 86 fL (HR 2.71, p=0.002) and a neutrophil count > 8.6 x109/L (HR 5.39,
p=0.002) maintained independent association with OPO. L1 Montreal location
at diagnosis (HR 2.80, p=0.005) and having suffered a previous OPO (HR 3.08,
p<0.001) were also independently associated with OPO in the final model.
Conclusion: Consistently abnormal albumin level, platelet count, MCV and neu-
trophil count are associated with subsequent OPO development in patients with
Crohn’s disease. These tests may signal risk of development of subsequent OPO,
and may provide a rationale for escalation of therapy. These findings require
validation in an external cohort.
5.4. Introduction
Crohn’s disease is a chronic inflammatory condition of the human gastrointestinal
tract of undetermined aetiology. It is characterized by a relapsing and remit-
ting course (Munkholm et al. 1995) and by significant morbidity from chronic
abdominal pain, diarrhoea, perianal abscess and fistula formation, bowel stenosis
and obstruction, internal fistulization and bowel perforation.(Lazarev et al. 2010;
Cosnes, Nion-Larmurier, et al. 2005; Ramadas et al. 2010; Tarrant et al. 2008;
Thia et al. 2010; Magro et al. 2014)
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Treatment with corticosteroids, the thiopurines azathioprine and 6-mercaptopurine,
methotrexate, the anti tissue necrosis factor (TNF) alpha inhibitors infliximab
and adalimumab and the anti-integrins natalizumab and vedolizumab have been
demonstrated to reduce evidence of active Crohn’s disease when measured by the
Crohn’s disease activity index (CDAI) and by endoscopic assessment of bowel mu-
cosa. (Markowitz 2003; Pearson, May, G. Fick, et al. 2000; Feagan, Rochon, et al.
1995; Feagan, Fedorak, et al. 2000; J. F. Colombel et al. 2010; J.-F. Colombel
et al. 2007; Sandborn, J. F. Colombel, et al. 2005; Sandborn, Feagan, et al. 2013;
Benchimol et al. 2008) There is observational evidence that anti TNF alfa therapy
is associated with a reduction in rates of intestinal surgery, (Feagan, Panaccione,
et al. 2008) and conflicting evidence that azathioprine and 6-mercaptopurine are
associated with a reduction in rates of intestinal surgery, or rates of stenotic or
penetrating complications. (Ramadas et al. 2010; Cosnes, Nion-Larmurier, et al.
2005; Feagan, Panaccione, et al. 2008; Chatu et al. 2014; Lakatos et al. 2012) Im-
munomodulatory therapy in Crohn’s disease carries a significant side effect profile.
For patients without symptoms from their Crohn’s disease, a decision to embark
on long term immunomodulatory therapy rests on assessment of risk of develop-
ment of a poor long term outcome, and the magnitude of expected reduction in
this risk associated with medication use.
Features of a patient’s clinical presentation and early disease course allow some
prediction of the likelihood of a subsequent poor clinical course. This allows clin-
icians scope to limit immunomodulatory medication exposure to patients most
likely to benefit from them. Age <16 at diagnosis, perianal disease at diagnosis,
and requirement for corticosteroids to control the first flare of disease are published,
validated and widely used predictors of a poor outcome described as disabling dis-
ease.(Beaugerie, Seksik, et al. 2006; Loly, Belaiche, and Louis 2008) Additionally
there are published data demonstrating an association between NOD2 genotype
and development of stenotic or penetrating complications (Adler et al. 2011), active
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smoking with penetrating complications,(Louis, Michel, et al. 2003) Anti Saccha-
romyces cerevisiae antibody (ASCA) positivity with small bowel stenosis (Vasil-
iauskas et al. 2000; Forcione et al. 2004) and raised CRP and platelet count at
diagnosis with subsequent bowel resection. (Boirivant et al. 1988; Loly, Belaiche,
and Louis 2008; Henriksen et al. 2008)
Current predictors of poor outcome suffer from low discriminatory power in
identifying patients likely to follow a complicated disease course, and from non-
uniformity of outcome measure. Further stratification of patients into those more
and less likely to follow a poor clinical course would allow improved tailoring of
immunomodulatory therapy, and improved management.
Published literature associating laboratory testing and long term outcome in
Crohn’s disease demonstrate an association between both a high CRP and a high
platelet count at diagnosis, with subsequent intestinal surgery.(Loly, Belaiche,
and Louis 2008; Henriksen et al. 2008) Additionally an association has been ob-
served between haemoglobin level and subsequent surgery or disease complica-
tion. (Rieder et al. 2014) There are little published data analyzing the association
between longitudinal laboratory testing and subsequent outcome. Longitudinal
laboratory testing is a routine part of the management of patients with Crohn’s
disease. Testing is performed to assess inflammatory status, nutritional status,
and to monitor for side effects from prescribed medications. These results repre-
sent a silo of objective clinical information which may provide useful prediction
of future disease course. We hypothesize that these results contain a measurable
signal that is associated with active and progressive Crohn’s disease, and that this
signal is associated with the subsequent development of an objective poor outcome
(OPO).
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5.5. Objective
To study the correlation between longitudinal laboratory testing and subsequent
development of bowel stenosis, bowel perforation or intra-abdominal fistula for-
mation in patients with Crohn’s disease.
5.6. Patients and methods
This was a single centre observational longitudinal cohort study. All patients with
a diagnosis of Crohn’s disease made between 1st January 1994 and 31st March
2008, managed at the Inflammatory Bowel Diseases Unit at the Royal Brisbane and
Women’s Hospital (RBWH, Brisbane, Australia), were invited to participate in the
research programme. Serological, epidemiological, clinical and genetic data were
obtained for each patient. Further clinical data was obtained through retrospective
review of the clinical record.
Ethical approval for the study was obtained through the Royal Brisbane and
Women’s Hospital ethics committee. All participating patients consented to take
part in the research programme.
5.6.1. Definitions
The date of diagnosis was defined as the first date when the patient was felt to
meet diagnostic criteria for Crohn’s disease (Lennard-Jones 1989) by the treating
physician. This was usually when tissue was first obtained at either colonoscopy
or surgery, confirming chronic bowel inflammation in the setting of chronic ab-
dominal symptoms. An OPO was defined as the first observation of an intestinal
fistula, stenosis or perforation. This observation could be made at surgery, on
macroscopic examination of a surgical specimen, at colonoscopy or gastroscopy, on
computed tomography (CT) scanning, on magnetic resonance imagining (MRI),
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or in the case of enterocutaneous fistulae on clinical examination. Perianal fistulae
were not considered an OPO. An OPO was considered resolved 2 years following
the time it was last observed. Resolution could result from surgery, or from the
passage of time. The observation period prior to the development of an OPO in
which laboratory data were examined was defined as follows: Ninety days follow-
ing date of diagnosis, ninety days prior to first identification of the OPO, ninety
days prior to censoring at end of study period if no OPO was identified in the
observation period, and if the observation period followed a previous OPO, fol-
lowing resolution of the previous OPO (Figure 5.1). Laboratory variables taken
within 90 days of abdominal surgery were excluded. These temporal exclusions
were set to minimize the influence of two possible sources of bias. The first pos-
sible bias is that the presence of an occult, undiagnosed OPO, either at diagnosis
or in the months leading up to OPO, would lead this analysis to misinterpret an
association between occult OPO presence and subsequent OPO identification as
an association between laboratory variables taken in the absence of an OPO and
subsequent OPO development. The second possible bias is that an association
between abdominal surgery and abnormal laboratory values, and an association
between abdominal surgery and subsequent OPO development, would be misin-
terpreted as an association between abnormal laboratory values and subsequent
OPO development.
5.6.2. Inclusion and exclusion criteria
All included patients met criteria for a diagnosis of Crohn’s disease.(Lennard-Jones
1989) These were consistent with the Lennard-Jones criteria, however patients who
did not undergo surgery, and therefore did not have a transmural surgical specimen
for examination, were not required to demonstrate evidence of transmural bowel
involvement. For these patients evidence of chronic mucosal bowel inflammation
in a typical distribution (ileal only, or non-continuous colonic) was considered
adequate for diagnosis. All early clinical information was reviewed to confirm
that diagnostic criteria were met. Patients who did not have 5 years of follow-up
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Figure 5.1
Cartoon demonstrating observation period from which lab data are taken.
This patient contributes two observation periods to the analysis: the first
leading up to identification of an ileal stricture on CT scan, the second when
he/she reaches the end of the study period without suffering a second OPO.
The second observation period does not begin until 2 years have passed
without observation of the previous ileal stricture.
data available were not included in the analysis. OPO events which had less than
two laboratory variables recorded in the immediately preceding observation period
were excluded. OPO events which had an observation period of less than 180 days
were excluded.
5.6.3. Laboratory data
Laboratory data were obtained by matching identities to data from four sources:
AUSLAB (all laboratory results performed in public hospitals across Queensland
1st Jan 1999 to present), PARIS (historical database which records all laboratory
results performed in public hospitals in Brisbane 1st Jan 1985 - 1st Jan 1999),
Queensland Medical Laboratories (QML, private laboratory database covering all
of Queensland 1st Jan 1995 to present) Sullivan and Nicholaides Pathology (SNP,
private laboratory database covering all of Queensland 1st Jan 2001 – present).
QML and SNP are the two major private pathology providers in Queensland.
Patients were matched by surname, first-name, date of birth (DOB) and sex.











Area under curve calculation: for variables that usually rise with inflammation
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Figure 5.3
Area under curve calculation: for variables that usually fall with inflammation
or malnutrition (albumin, haemoglobin, ferritin, serum iron, MCV, transferrin
saturation, serum folate, red cell folate, vitamin D, vitamin B12)
C reactive protein (CRP,mgL−1), erythrocyte sedimentation rate (ESR,mm/h),
haemoglobin level (g L−1), white blood cell count (WBC, x109/L), platelet count
(x109/L), neutrophil count (x109/L), mean cell volume (MCV, fL), faecal calpro-
tectin (µg g−1 faeces), albumin (g L−1), alanine transaminase (ALT, U/L), serum
ferritin (mgL−1), serum iron (µmol L−1), transferrin saturation (%), vitamin D
level (nmol L−1), red cell folate (nmol L−1), serum folate (nmol L−1) and vitamin
B12 level (pmol L−1) were analyzed. When analyzed as continuous variables, val-
ues reported as below the lowest detectable level were considered equal to zero,
while all values reported above a highest detectable level were considered equal
to that highest detectable level. These considerations were most important for
CRP which had a lower limit of detection of 5 mgL−1 in the 1990’s, reducing to
2 mgL−1 in 2006.
A representative value (laboratory variable Area Under Curve, lvAUC) for each
laboratory variable, for each observation period, was calculated using a variation
of the Area Under the Curve (AUC) using all eligible dated laboratory values
ordered temporally (valuen taken at timen, see figures 5.2, 5.3).
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5.6.4. Statistical analysis
Statistical analysis was performed in the R statistical computing environment. (R
Core Team 2014) Correlation between lvAUC values variables and OPO was ana-
lyzed using Cox regression, allowing study subjects to experience multiple outcome
events as described in the method by Prentice et al.(Prentice, B. J. Williams, and
Peterson 1981, see Figure 5.1). In short, predictor variables were analyzed as a
function of time to event from date of diagnosis or from resolution of the immedi-
ately preceding OPO, whichever was the most recent 5.1. In the exploratory anal-
ysis, lvAUC for each variable observed over the immediately preceding observation
period was correlated with OPO using univariate Cox regression. lvAUC variables
with a p-value of association <0.2 were then entered into a multivariate model in a
stepwise fashion, retaining those with independent correlation (p<0.05) in a mul-
tivariate model. To make the analysis more clinically relevant, lvAUC variables
were converted to dichotomous categorical variables, with optimized cut-off values
determined using an automated algorithm. These relationships were adjusted for
potential confounding by including the following variables in a final multivariate
model: age at diagnosis, sex, date of diagnosis, Montreal classification disease
location at diagnosis,(Silverberg et al. 2005) perianal disease at diagnosis, smok-
ing status at diagnosis, having experienced a previous OPO, ATG16L1 genotype,
NOD2 genotype, IL23R genotype, and use of intravenous steroids for first disease
flare. Bias introduced through relatedness between repeated OPO events observed
in the same patient was controlled for by including the variable experienced previ-
ous OPO in the multivariate model.
5.7. Results
291 patients contributed data for analysis.(Figure 5.4) Demographics are shown
in Table 5.1. 309 OPO events were observed over a median follow-up period of
10.49 years. These comprised 179 independent stenoses, 30 independent fistulae,
35 independent perforations and 65 combination stenosis and perforation/fistula
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events (combination events). 45 stenoses, 18 perforations, 8 fistulae and 16 com-
bination events occurred within 9 months of diagnosis and were excluded. 18
stenoses, 3 perforations, 7 fistulae and 11 combination events occurred without
laboratory data in the preceding observation period and were therefore excluded.
116 independent stenoses, 14 independent perforations, 15 independent fistulae
and 38 combination events contributed to the analysis. 162 patients suffered no
OPO event over the observation period, 87 patients suffered one, 32 suffered 2, 8
suffered 3, and 2 suffered 4. The median number of laboratory results for each
test over each observation period are tabulated in Table 5.2. Data for faecal cal-
protectin were available for less than 1/3 of all observation periods, partly because
faecal calprotectin was only used routinely to aid management after 2008.
Demographics
Age (mean, years) 27.3
Female 55.33 %
Caucasian Australian 86.25 %
Smoker at Diagnosis 50.17 %
Family History IBD 27.49 %
Follow-up (median, years) 10.49














Platelet Count Haemoglobin Albumin Level CRP Faecal Calprotectin
Proportion of observation 1 1 1 0.97 0.3
periods with results
Median number of 21 (11-36) 21 (11-36) 18 (10-32) 15 (8-27) 4 (2-6)
results per observation period
Median tests per 4.72 (3.07-7.12) 4.73 (3.11-7.27) 4.33 (2.78-6.5) 3.8 (2.45-5.92) 1.88 (1.2-2.68)
year
Table 5.2
Number of laboratory tests (prior to development of OPO, or prior to censuring at study end), used to calculate lvAUC value for each
observation period.
Number of OPO or censored events = 418.
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lvAUC values for all analyzed laboratory variables are shown in Table 5.4, strat-
ified by whether the observation period ended in an OPO or in censoring. Figure
5.5 demonstrates the relationship between raw albumin results and the lvAUC
value over one observation period for one patient. Correlation between continu-
ous lvAUC laboratory values and OPO are tabulated in Table 5.4. Correlation
between possible confounding variables and OPO are tabulated in Table 5.5. Hav-
ing suffered a previous OPO, and L1 Montreal location at diagnosis, were both
positively correlated. There was a trend for younger age to be correlated with
OPO, while presence of perianal disease at diagnosis and IV steroid use at diag-
nosis were not correlated. Optimal cutoff values for conversion of continuous to
categorical laboratory variables are shown in Table 5.6. A final multivariate model
of independent variables is tabulated in Table 5.7. Table 5.8 shows the sensitivity,
specificity, positive and negative predictive value of these features in prediction of
development of OPO when applied to the derivation cohort.
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Figure 5.5








Variable OPO No OPO p-value (t-test)
Haemogobin (g L−1) 131.48 (123.91 - 140.22) 135.65 (127.38 - 144.77) 0.003*
MCV (fL) 89 (85.2 - 93.02) 90.34 (87.84 - 94.59) 0.005*
Platelet count (x109/L) 299.39 (259.26 - 361.02) 274.03 (237.56 - 317.88) <0.001 **
White Cell Count (x109/L) 7.71 (6.32 - 9.32) 6.94 (5.93 - 8.17) <0.001 **
Neutrophil Count (x109/L) 5.12 (4.13 - 6.33) 4.39 (3.56 - 5.43) <0.001 **
Albumin (g L−1) 40.01 (37.32 - 41.68) 41.56 (39.61 - 43.5) <0.001 **
ALT (U/L) 15.77 (11.21 - 20.21) 17.97 (13.83 - 25.58) <0.001 **
CRP (mgL−1) 8.65 (3.97 - 16.61) 5.04 (1.72 - 10.46) <0.001 **
ESR (mm/h) 15.28 (8.73 - 23.57) 11.99 (7.24 - 21.38) 0.073
Calprotectin (µg g−1) 200.39 (54.62 - 341.09) 141.7 (60 - 402.8) 0.766
Ferritin (µg L−1) 63.65 (38.4 - 100) 77.61 (42.7 - 127.15) 0.041*
Serum Iron (µmol L−1) 11.9 (7.97 - 15.21) 14.61 (11.23 - 18.14) <0.001 **
Transferrin Saturation (%) 18.64 (13.6 - 26.37) 22.98 (16.81 - 28.12) 0.005*
Vitamin D (nmol L−1) 80.7 (69 - 104.8) 79.09 (66.12 - 99.27) 0.52
Serum Folate (nmol L−1) 30.62 (12.92 - 34.72) 32.78 (28.6 - 38.9) 0.154
Red Cell Folate (nmol L−1) 1045.9 (788.4 - 1369.58) 1106.75 (857.9 - 1441.86) 0.162
B12 (pmol L−1) 388.48 (294.31 - 504.18) 324.18 (244 - 426.78) 0.015*
Table 5.3
Comparison of lvAUC values over observation periods prior to OPO events, with lvAUC values over observation periods prior to
censoring.
lvAUC values reported as Median (Lower Quartile - Upper Quartile)
p-value is for a two tailed t-test comparing the difference of two means.
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β coefficient Hazard Ratio p-value †
Haemogobin -0.019 0.98 0.002 ?
MCV -0.038 0.96 0.002 ?
Platelet count 0.004 1.00 <0.001 ??
White Cell Count 0.140 1.15 0.001 ?
Neutrophil Count 0.225 1.25 <0.001 ??
Albumin -0.131 0.88 <0.001 ??
ALT -0.030 0.97 <0.001 ??
CRP 0.022 1.02 0.001 ?
ESR 0.005 1.01 0.390
Calprotectin 0.000 1.00 0.854
Ferritin -0.003 1.00 0.005 ?
Serum Iron -0.072 0.93 <0.001 ??
Transferrin Saturation -0.026 0.97 0.017 ?
Vitamin D 0.008 1.01 0.277
Serum Folate -0.065 0.94 0.140
Red Cell Folate -0.001 1.00 0.100
B12 0.001 1.00 0.043 ?
Table 5.4
Univariate Cox regression associating lvAUC values and OPO events.
† p-value for Log Rank test of association.
? p<0.05
?? p<0.001
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β coefficient Hazard Ratio p-value †
Age at Diagnosis -0.012 0.99 0.054
Sex (Female) -0.004 1.00 0.979
Date of Diagnosis 0.000 1.00 0.633
Perianal Disease at Diagnosis -0.037 0.96 0.893
Smoking at Diagnosis 0.095 1.10 0.234
Smoking at OPO event 0.548 1.73 0.001 ?
Previous OPO 0.494 1.64 0.004 ?
IV Steroids at Diagnosis -0.234 0.79 0.273
IL23R status (GG vs AG) -0.152 0.86 0.701
ATG16L1 status (Reference
Level A)
AG 0.368 1.44 0.193
G 0.463 1.59 0.111
Number of NOD2 Mutations
(Reference Level 0)
1 -0.170 0.84 0.397
2 0.037 1.04 0.899
Montreal Location at Diagnosis
(Reference Level L2)
L1 0.637 1.89 0.004 ?
L3 0.424 1.53 0.070
Table 5.5
Univariate cox regression: Other confounding variables.
† p-value for Log Rank test of association.
? p<0.05
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Haemoglobin (Sex Adjusted) <129 g L−1 (m)
<114 g L−1 (f)
Haemoglobin <115 g L−1
MCV <86 fL
Platelet Count >370 x109/L
White Cell Count >11.5 x109/L
Neutrophil Count >8.6 x109/L




Faecal Calprotectin >174 µg g−1
Ferritin <53 µg L−1
Iron <7 µmol L−1
Transferrin Saturation <13 %
Vitamin D <77 nmol L−1
Serum Folate <15 nmol L−1
Red Cell Folate <360 nmol L−1
Vitamin B12 <335 pmol L−1
Table 5.6
Optimal cutoff for conversion from continuous to categorical lvAUC variables.
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β Coefficient Odds Ratio p-value †
lvAUC albumin level < 37 0.91 4.41 <0.001 ??
lvAUC platelet count > 370 0.46 2.22 0.027 ?
lvAUC MCV < 86 0.48 2.71 0.007 ?
lvAUC neutrophil count > 8.6 1.87 5.39 <0.001 ??
Montreal Location at Diagnosis (reference
level = L2)
L1 0.58 2.53 0.011 ?
L3 0.30 1.24 0.217
Previous Event 0.48 2.87 0.004 ?
Table 5.7
Cox regression: multivariate analysis.
† Log Rank test.
? p<0.05
?? p<0.001
Included OPO events or censored observation periods =412.
No OPO OPO Sens Spec PPV NPV ? Duration Observation
† 0 70 26 1.00 0.30 0.44 0.73 7.1
1 105 67 0.86 0.30 0.49 0.73 5.4
2 44 52 0.49 0.76 0.61 0.65 3.7
3 10 26 0.20 0.95 0.75 0.60 2.7
4 1 10 0.06 0.99 0.83 0.57 2.5
5 1 0 0.00 1.00 0.00 0.56 3.1
Table 5.8
Contingency table.
† Number of predictors (lvAUC albumin level, lvAUC platelet count, lvAUC
MCV, lvAUC neutrophil count, ileal disease location, preveious event)
? Median value in years.
n=418.
Sens=Sensitivity, Spec=Specificity, PPV=positive predictive value, NPV =
negative predictive value.
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5.8. Discussion
5.8.1. Prediction of OPO
In this study an lvAUC albumin < 37g L−1, lvAUC platelet count > 370 x109/L,
lvAUCMCV < 86 fL and an lvAUC neutrophil count > 8.6 x109/L were associated
with subsequent development of an OPO, predominantly stenosis, in patients with
Crohn’s disease. These observations provide data to support the concept of using
longitudinal laboratory testing to predict subsequent disease course in patients
with Crohn’s disease.
In our experience laboratory testing for patients with Crohn’s disease tends to
be reactive, performed to correlate current symptoms with objective inflammatory
or nutritional markers, or to assess the response of these markers to a change in
therapy. This study demonstrates that these same laboratory variables can provide
an objective longitudinal assessment of inflammatory and nutritional status, an
assessment which correlates with the subsequent development of an OPO. It is
noteworthy that the cut-off lvAUC values that were associated with OPO for
each variable in our study were not markedly abnormal when compared to normal
ranges for individual results. Figure 5.5 demonstrates that lvAUC is a markedly
different entity to a single laboratory value, and that only with consistent and
significant abnormality in individual results is an lvAUC value moved away from
normality. lvAUC data cannot be compared to single laboratory results, and must
be considered without referring to the normal range for individual results.
Faecal calprotectin was used routinely in the management of our patients from
2008, and therefore a small number of observation periods had faecal calprotectin
data to use for analysis. There were not enough data, and not enough statis-
tical power, to adequately assess this biomarker which may provide prognostic
information in future studies.
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The aim of this analysis was to identify persistent laboratory abnormalities
which were associated with a clinically significant outcome event. The dominant
observed OPO was stenosis, partly due to the exclusion of half of all observed
fistulizing or penetrating complications because they occurred within 9 months
of diagnosis. The absolute rate and relative proportion of intra-abdominal steno-
sis, perforation and fistula formation in our cohort is similar to published cohorts
when represented by cumulative Montreal phenotype classification.(Silverberg et
al. 2005; Tarrant et al. 2008) We believe that this is representative of the spec-
trum of long term complications suffered by patients with Crohn’s disease, and
that therapy initiated with the goal of preventing the development of long term
complications would be given predominantly to prevent bowel stenosis.
5.8.2. Objectivity In outcome assessment
Intestinal surgery is a commonly used endpoint in longitudinal studies of Crohn’s
disease.(Ramadas et al. 2010; Chatu et al. 2014; Feagan, Panaccione, et al. 2008)
We elected to use development of OPO and not performance of intestinal surgery
as our primary endpoint in this study as we consider that the decision to perform
surgery may be influenced by subjective factors (physician and surgeon opinion of
what is a reasonable indication for surgery, patient agreement to undergo surgery)
and may not be a truly objective marker of outcome. This is demonstrated by
varied rates of intestinal surgery in cohorts of patients with Crohn’s disease, across
time periods and across geographic location.(Wolters, M. G. V. M. Russel, and
Stockbrügger 2004; Ramadas et al. 2010) The international IBD community have
proposed a more objective definition of long term outcome in Crohn’s disease, the
Lemann score.(Pariente, Mary, et al. 2015) This score assigns a numeric represen-
tation of outcome based on observation of stenosis, perforation and fistulization
made at ileocolonoscopy, gastroscopy, surgery, on examination of macroscopic his-
tological specimens, clinical examination and cross sectional imaging. It is complex
and has not yet been routinely taken up in observational Crohn’s disease research
to date. However, this score is likely to provide a more objective and standardized
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measure of longitudinal outcome in Crohn’s disease, which may translate better
between patients in different time periods and different geographic locations, and
allow closer comparison between different research cohorts.
5.8.3. Weaknesses in study design
This was an observational study and so was inherently subject to bias. We have
attempted to minimize bias through study design, although acknowledge that
unidentified bias may have influenced the observed associations.
Delay in diagnosis of perforation, fistula or stenosis mean that the observed as-
sociation between abnormal tests and OPO may be due to an undiagnosed OPO
being present when the tests were performed. This would reduce this study to
observing that patients with an OPO have abnormal laboratory values. We at-
tempted to minimize this bias by excluding laboratory results taken in the 90 days
leading up to the first identification of an OPO. We also excluded results taken
within 90 days of diagnosis, where we feel actual or imminent OPO is common
and often not observed on initial testing.
Laboratory tests performed near the time of abdominal surgery were excluded
from the analysis. Surgery could be considered a surrogate marker for a more se-
vere phenotype, and this exclusion reduced the possible bias introduced by surgery
itself causing abnormal lab tests. Without this restriction a true association be-
tween intestinal surgery and subsequent development of an OPO could be inter-
preted as an association between abnormal blood results (consequent to surgery)
and the subsequent development of an OPO.
When this analysis was run including all laboratory results the associations
were similar. However, because of the biases mentioned above, we feel that the
exclusions used mean it is more likely we have observed a true association between
laboratory testing taken when a patient is free of an OPO, and the subsequent
development of an OPO.
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Many of our patients suffered OPO at diagnosis or early in their disease course
and then were observed for many years. We used the described study design to
allow inclusion of data collected subsequent to a resolved OPO, correlating it with
the subsequent development of a new OPO. Because of this study design, single
patients may have overly influenced the observed result by contributing multiple
OPO events to the analysis - 48 patients contributed more than one OPO event to
the analysis. This influence was controlled for by including a relatedness variable
(experience of previous OPO) in the final multivariate model. Without this study
design the application of this data would be limited to patients early in their
disease course. The described study design allows translation of the observed
associations to patients both early and late in their disease course, and to patients
who have suffered a previous OPO.
Laboratory tests were more likely to be performed frequently when patients
were unwell. Patients taking immunomodulatory therapy also had blood tests
regularly taken when they were well, to monitor for medication side effects. As
a potential source of bias this was minimized by using all available laboratory
data which met temporal criteria, including those requested by general practition-
ers. Secondly, we feel that using lvAUC to represent laboratory variables gave a
longitudinal assessment of inflammatory and nutritional status, less influenced by
clusters of multiple testing at times when patients were unwell.
MCV is influenced by thiopurine and methotrexate immunotherapy. It is pos-
sible that an association between a low MCV and subsequent OPO occurrence
is due to the effect of these drugs on both the MCV, and the natural history of
the disease. This criticism does not extend to albumin level, platelet count or
neutrophil count.
Patient reported symptoms of diarrhoea and pain were not collected in this
study, and we therefore do not know if the observed associations are independent
of patient symptoms. For patients with Crohn’s disease with significant symptoms
attributable to their disease, estimation of future complication risk contributes
little to selection of treatment. These patients are likely to want to take stronger
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therapy to control their symptoms. It is for patients without marked symptoms
that estimation of future complication risk, such as that provided by longitudinal
laboratory data, would be most useful. We felt that collection of patient reported
symptoms through retrospective clinical review would produce unreliable data,
and we elected not to do it. This meant that all analyzed factors were objective,
however we do not know if they were independent of patient symptoms.
5.9. Conclusion
A consistently low serum albumin level, consistently high platelet count, con-
sistently low MCV and consistently high neutrophil count were associated with
subsequent OPO, predominantly stenosis, in patients with Crohn’s disease. In ad-
dition to recognized markers of poor outcome in Crohn’s disease, these laboratory
tests may prove to be useful as markers of risk of development of subsequent OPO,
and provide a rationale for escalation of therapy. These findings require validation
in an external cohort.
6. A consistently low serum albumin
or high C reactive protein is associ-
ated with subsequent development
of perianal fistulae in patients with
Crohn’s disease.
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6.3. Abstract
Aim: To study the correlation between longitudinal laboratory testing and subse-
quent development of perianal fistulae in patients with Crohn’s disease.
Methods: Patients diagnosed with Crohn’s disease between 1st Jan 1994 and 1st
March 2008, with more than five years of clinical follow-up, were analyzed. Pa-
tients developing a perianal fistula within 9 months of diagnosis were excluded.
Laboratory data were represented by the area under the curve of values measured
in the complication free period leading up to development of a perianal fistula.
Association between laboratory values (C reactive protein, erythrocyte sedimen-
tation rate, platelet count, haemoglobin level, mean cell volume, white blood cell
count, neutrophil count, albumin, alanine transaminase, vitamin D, vitamin B12,
folate, faecal calprotectin, serum iron, transferrin saturation and ferritin level) and
perianal fistula development was analyzed using Cox regression.
Results: 268 patients met inclusion criteria and were observed for a median of
9.35 (Interquartile range (IQR) 6.41-13.50) years. 49 developed a perianal fistula
a median 4.43 years (IQR 3.10-8.54 years) after diagnosis. Blood testing was per-
formed a median of 4.33 (IQR 2.88-6.66) times per year for each patient. After
multivariate analysis with inclusion of potentially confounding variables, a CRP
consistently >11 mg/L (Hazard ratio (HR) 2.63, p=0.003), an albumin level con-
sistently <38 g/L (HR 2.66, p=0.002), age at diagnosis <32 (HR 3.86, p=0.005)
and L2 Montreal disease location (HR 2.39, p=0.017) were independently associ-
ated with development of perianal fistulae.
Conclusion: An albumin consistently <38 g/L or a CRP consistently >11 mg/L
are associated with subsequent development of perianal fistulae in patients with
Crohn’s disease. Serial monitoring and longitudinal analysis of these variables may
aid in identifying patients at risk of developing perianal fistulae, and allow better
tailoring of preventative therapy. These findings need validation in an external
cohort.
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6.4. Introduction
Crohn’s disease is a chronic inflammatory condition of the human gastrointestinal
tract of undetermined aetiology. It is characterized by a relapsing and remit-
ting course (Munkholm et al. 1995) and by significant morbidity from chronic
abdominal pain, diarrhoea, perianal abscess and fistula formation, bowel stenosis
and obstruction, internal fistulization and bowel perforation.(Lazarev et al. 2010;
Cosnes, Nion-Larmurier, et al. 2005; Ramadas et al. 2010; Tarrant et al. 2008;
Thia et al. 2010; Magro et al. 2014) Chronic perianal fistulae may be present
for many years in patients with Crohn’s disease, and cause significant morbidity
from pain, faecal leakage and anal stenosis. Perianal fistulae are present in up
to 20% of patients at diagnosis, and develop in a further 10% over the next five
years.(Schwartz et al. 2002; Cosnes, S. Cattan, et al. 2002)
Infliximab and adalimumab have been shown to aid healing of perianal fistu-
lae.(Present et al. 1999; J.-F. Colombel et al. 2007) In a meta analysis, thiopurine
use was associated with resolution of perianal fistulae, although this effect has
not been demonstrated as a primary endpoint in a controlled trial.(Pearson, May,
G. H. Fick, et al. 1995) The current paradigm of medical management in Crohn’s
disease is that enduring control of bowel inflammation reduces tissue damage,
and reduces long term risk of complications such as bowel perforation or stenosis.
There are no published data demonstrating that immunomodulatory therapy re-
duces the risk of developing a perianal fistula. However, it is attractive to consider
that such complications may be prevented with medical therapy.
Immunomodulatory therapy in Crohn’s disease carries a significant side effect
profile. For patients without significant symptoms from their Crohn’s disease, a
decision to embark on long term immunomodulatory therapy rests on assessment of
risk of development of a poor long term outcome, and the magnitude of expected
reduction in this risk associated with medication use. Risk of development of
perianal fistulae forms part of this assessment.
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Most published data observe that perianal fistulae are more commonly observed
in patients with colonic disease location.(D. R. Williams et al. 1981; Rankin et al.
1979; Veloso et al. 2001; Tang, Rawsthorne, and Bernstein 2006) Data demonstrat-
ing either no association between disease location and development of perianal fis-
tulae,(Lapidus 2006) or an association between ileal disease location and perianal
disease (Eglinton et al. 2012) have also been published. In both of these studies
a markedly high proportion of each cohort had L2 Montreal location of disease
(52% and 42% respectively). Perianal location of disease forms part of the diag-
nostic criteria for Crohn’s disease.(Lennard-Jones 1989) Intestinal penetrating or
stenotic complications, and associated surgery are less common in colonic Crohn’s
disease. Hence a transmural intestinal specimen is less commonly available to
aid diagnosis in colonic inflammatory bowel disease, and diagnosis depends more
heavily on assessment of disease location and mucosal histology. These observa-
tions suggest that the association between location of disease and perianal fistula
formation is dependent on how colonic inflammatory bowel disease is classified in
a cohort. Stringent interpretation of a diagnosis of Crohn’s disease will require the
presence of extracolonic disease (perianal, small bowel or upper gastrointestinal)
or granulomas on biopsy in addition to colonic disease location and histological ev-
idence of chronic inflammation. Less stringent interpretation may require varying
degrees of discontinuous colonic involvement and histological evidence of chronic
inflammation only. Differences in interpretation of diagnostic criteria for colonic
Crohn’s disease are likely to explain differing association of disease location with
perianal disease between cohorts.
par
Young age at diagnosis and complicated intestinal disease (perforation, fis-
tula formation or stenosis) have also been associated with perianal fistula forma-
tion.(Eglinton et al. 2012; Lapidus 2006)
Published literature associating laboratory testing and long term outcome in
Crohn’s disease demonstrate an association between a high CRP at diagnosis,
and a high platelet count at diagnosis, with subsequent intestinal surgery.(Loly,
Belaiche, and Louis 2008; Henriksen et al. 2008) We are not aware of published
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data analyzing the association between laboratory testing and subsequent peri-
anal fistula formation. Data allowing further stratification of patients into those
more and less likely to develop a perianal fistula could allow improved tailoring of
immunomodulatory therapy in Crohn’s disease. Longitudinal laboratory testing
is a routine part of the management of patients with Crohn’s disease. Testing
is performed to assess inflammatory status, nutritional status, and to monitor for
side effects from prescribed medications. These results represent a silo of objective
clinical information which may provide useful prediction of future disease course.
We hypothesize that these results contain a measurable signal that is associated
with active and progressive Crohn’s disease, and that this signal is associated with
the subsequent development of a perianal fistula.
6.5. Materials and methods
6.5.1. Patients
This was a single centre observational longitudinal cohort study. All patients with
a diagnosis of Crohn’s disease made between 1st January 1994 and 31st March
2008, managed at the Inflammatory Bowel Diseases Unit at the Royal Brisbane and
Women’s Hospital (RBWH, Brisbane, Australia), were invited to participate in the
research programme. Serological, epidemiological, clinical and genetic data were
obtained for each patient. Further clinical data was obtained through retrospective
review of the clinical record.
6.5.2. Inclusion and exclusion criteria
All patients met criteria for a diagnosis of Crohn’s disease. (Lennard-Jones 1989)
These were essentially the Lennard-Jones criteria, however patients who did not
undergo surgery, and therefore did not have a surgical specimen for examination,
were not required to demonstrate evidence of transmural bowel involvement. For
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these patients evidence of chronic mucosal bowel inflammation in a typical distri-
bution (ileal only, or non-continuous colonic) was considered adequate for diagno-
sis. All early clinical information was reviewed to confirm that diagnostic criteria
were met. Patients who did not have 5 years of follow-up data available were not
included in the analysis. Patients who developed a perianal fistula within 270 days
of diagnosis were excluded from analysis. This exclusion was made because little
longitudinal laboratory data were available for these patients.
6.5.3. Definitions
The date of diagnosis was defined as the first date when the patient was felt to meet
diagnostic criteria for Crohn’s disease by the treating physician.(Lennard-Jones
1989) This was usually when tissue was first obtained at either colonoscopy or
surgery, confirming chronic bowel inflammation in the setting of chronic abdominal
symptoms. A perianal fistula was defined as a sinus in the perianal skin weeping
faeces, pus or serous fluid. A perianal abscess without an identified sinus tract was
not considered a perianal fistula. Perianal fistulae could be identified on clinical
examination, at perianal surgery, on pelvic magnetic resonance imagining (MRI)
or endoanal ultrasound. The observation period prior to the development of a
perianal fistula in which laboratory data were examined was defined as follows;
90 days following date of diagnosis, ninety days prior to first identification of a
perianal fistula and ninety days prior to censoring at the end of the study period
if no perianal fistula developed over the observation period. Laboratory variables
taken within ninety days of abdominal surgery were excluded.
6.5.4. Laboratory data
Laboratory data were obtained by matching identities to four external laboratory
databases: AUSLAB (all laboratory results performed in public hospitals across
Queensland 1st Jan 1999 to present), PARIS (a historical database which records
all laboratory results performed in public hospitals in Brisbane 1st Jan 1985 - 1st
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Jan 1999), Queensland Medical Laboratories (QML, private laboratory database
covering all of Queensland 1st Jan 1995 to present) Sullivan and Nicholaides Pathol-
ogy (SNP, private laboratory database covering all of Queensland 1st Jan 2001 -
present). QML and SNP are the two major private pathology providers in Queens-
land. Patients were matched by surname, first name, date of birth (DOB) and
sex.
C reactive protein (CRP,mgL−1), erythrocyte sedimentation rate (ESR,mm/h),
haemoglobin level (g L−1), white blood cell count (WBC, x109/L), platelet count
(x109/L), neutrophil count (x109/L), mean cell volume (MCV, fL), faecal calpro-
tectin (µg g−1 faeces), albumin (g L−1), alanine transaminase (ALT, U/L), serum
ferritin (mgL−1), serum iron (µmol L−1), transferrin saturation (%), vitamin D
level (nmol L−1), red cell folate (nmol L−1), serum folate (nmol L−1) and vitamin
B12 level (pmol L−1) were analyzed. When analyzed as continuous variables, val-
ues reported as below the lowest detectable level were considered equal to zero,
while all values reported above a highest detectable level were considered equal to
that highest detectable level. These considerations were most important for CRP
which had a lower limit of detection of 5mg/L in the 1990’s, reducing to 2mg/L
in 2006.
A representative value (laboratory variable Area Under Curve, lvAUC) for each
laboratory variable, for each observation period, was calculated using a variation
of the Area Under the Curve (AUC) using all eligible dated laboratory values
ordered temporally (valuen taken at timen, see figures 6.1, 6.2).
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Figure 6.2
Area under curve calculation: for variables that usually fall with inflammation
or malnutrition (albumin, haemoglobin, ferritin, serum iron, MCV, transferrin
saturation, serum folate, red cell folate, vitamin D, vitamin B12)
6.5.5. Statistical analysis
Statistical analysis was performed in the R statistical computing environment.
(R Core Team 2014) Correlation between lvAUC values and first perianal fistula
was analyzed using Cox regression. In the exploratory analysis, the lvAUC for
each variable observed over the immediately preceding observation period was
correlated with perianal fistula formation using univariate Cox regression. lvAUC
variables with a p-value of association <0.2 were then entered into a multivariate
model in a stepwise fashion, retaining those with independent correlation (p<0.05).
To make the analysis more clinically relevant, laboratory variables were converted
to dichotomous categorical variables, with optimized cut-off values determined
using an automated algorithm.(see coding reference 15) These relationships were
then adjusted for potential confounding by including the following variables in
a final multivariate model: age at diagnosis, sex, date of diagnosis, Montreal
classification disease location at diagnosis,(Silverberg et al. 2005) smoking status
at diagnosis, ATG16L1 genotype, NOD2 genotype, IL23R genotype, and use of
intravenous steroids at first disease flare.
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6.5.6. Ethical considerations
Ethical approval for the study was obtained through the RBWH ethics committee.
All participating patients consented to take part in the unit’s research programme.
Consent was given for the use of routine clinical and laboratory data for research
purposes. It also covered the collection of serum, whole blood and bowel tissue
samples for research purposes.
6.6. Results
Of 360 patients assessed, 302 were observed for 5 or more years. 28 patients devel-
oped their first perianal fistula within 270 days of diagnosis and were excluded. 6
patients developed a perianal fistula with no preceding laboratory data and were
excluded. 268 patients were included in the analysis of whom 49 developed a pe-
rianal fistula a median 4.43 years (Intraquartile range IQR 3.10-8.54 years) after
diagnosis.(see Figure 6.3) The demographics of these patients are shown in Table
6.1. The median number of laboratory results for each test during each observa-
tion period is tabulated in Table 6.2. Data for faecal calprotectin were available
for 1/3 of all observation periods.
lvAUC values for all analyzed laboratory variables are shown in Table 6.3, strat-
ified by whether the observation period ended in a perianal fistula or in censoring.
Figure 6.4 demonstrates the relationship between raw CRP results and the lvAUC
value over one observation period for one patient. Correlation using Cox regression
between continuous lvAUC laboratory values and development of perianal fistulae
are tabulated in Table 6.4. Correlation between possible confounding variables
and perianal fistula are tabulated in Table 6.5. L2 Montreal location at diagnosis
was positively correlated, while there was a trend for younger age and female sex
to be correlated with development of perianal fistulae. Optimal cutoff values for
conversion of continuous to categorical laboratory variables are shown in Table



















6.6. A final multivariate model of independent variables is tabulated in Table 6.7.
Table 6.8 shows the sensitivity, specificity, positive and negative predictive value
of these features in prediction of development of perianal fistula when applied to
the derivation cohort.




Caucasian Australian 85.45 %
Smoker 51.87 %
Family History IBD 27.99 %
Follow-up (median, years) 10.64













Platelet Count Haemoglobin Albumin Level CRP ESR Faecal Calprotectin
Proportion of patients 1 1 1 0.99 0.98 0.39
with results
Median number of 30 (16-48) 30 (16-48) 26 (13-42) 20 (10-34) 17 (8-26) 4 (2-6)
results per observation period
Median tests per 4.33 (2.88-6.66) 4.35 (2.88-6.65) 3.89 (2.54-6.18) 3.47 (2.18-5.38) 2.99 (2.04-4.72) 1.81 (1.25-2.66)
year
Table 6.2
Number of laboratory tests (prior to development of fistula, or censuring at study end), used to calculate lvAUC value for each patient.
Number of perianal fistula events = 49.
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Figure 6.4







Variable Perianal Fistula No Perianal Fistula p-value (t-test)
Haemogobin (g L−1) 130.6 (122.07 - 137.95) 134.92 (127.24 - 143.9) 0.027*
MCV (fL) 88.9 (84.65 - 92.17) 89.99 (87.02 - 93.43) 0.06
Platelet count (x109/L) 313.55 (285.58 - 339.46) 281.27 (240.89 - 324.71) 0.006*
White Cell Count (x109/L) 7.88 (6.21 - 9.23) 7.26 (6.08 - 8.39) 0.094
Neutrophil Count (x109/L) 5.36 (4.26 - 6.51) 4.72 (3.77 - 5.67) 0.014*
Albumin (g L−1) 39.81 (37.42 - 41.33) 41.27 (39.61 - 43.16) 0.002*
ALT (U/L) 15.24 (10.72 - 19.61) 17.65 (13.71 - 23.5) 0.006*
CRP (mgL−1) 12.62 (6.2 - 20.03) 6.04 (2.65 - 11.01) 0.001*
ESR (mm/h) 21.9 (13.73 - 33.32) 12.41 (7.72 - 20.58) 0.001*
Calprotectin (µg g−1) 292.18 (212 - 780) 138.28 (59.86 - 333.33) 0.252
Ferritin (µg L−1) 59.97 (35.26 - 135.48) 71.52 (44.39 - 109.83) 0.547
Serum Iron (µmol L−1) 9.68 (6.52 - 13.05) 13.56 (10.39 - 17.11) <0.001 **
Transferrin Saturation (%) 17.03 (12.36 - 24.21) 21.15 (15.74 - 27.46) 0.002*
Vitamin D (nmol L−1) 68.6 (56.6 - 94) 81.22 (67.12 - 96.03) 0.642
Serum Folate (nmol L−1) 34.78 (34.26 - 35.3) 33.52 (28.49 - 41.96) 0.716
Red Cell Folate (nmol L−1) 934.32 (756.72 - 1434.95) 1092.32 (892.65 - 1389) 0.918
B12 (pmol L−1) 343.32 (299.05 - 575.35) 345.82 (253.78 - 452.09) 0.108
Table 6.3
Comparison of lvAUC values over observation periods prior to perianal fistula development, with lvAUC values over observation
periods prior to censoring.
lvAUC values reported as Median (Lower Quartile - Upper Quartile)
p-value is for a two tailed t-test comparing the difference of two means.
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β coefficient Hazard Ratio p-value †
Serum Iron -0.167 0.85 <0.001 ??
Albumin -0.141 0.87 0.001 ?
Transferrin Saturation -0.067 0.94 0.007 ?
MCV -0.051 0.95 0.041 ?
ALT -0.030 0.97 0.039 ?
Haemogobin -0.029 0.97 0.020 ?
Vitamin D -0.011 0.99 0.475
Ferritin -0.002 1.00 0.407
Red Cell Folate 0.000 1.00 0.854
B12 0.001 1.00 0.091
Calprotectin 0.002 1.00 0.057
Platelet count 0.004 1.00 0.027 ?
Serum Folate 0.018 1.02 0.771
ESR 0.033 1.03 0.001 ?
CRP 0.060 1.06 <0.001 ??
White Cell Count 0.154 1.17 0.051
Neutrophil Count 0.288 1.33 0.003 ?
Table 6.4
Univariate Cox regression associating continuous lvAUC values and perianal
fistula events.
† p-value for Log Rank test of association.
? p<0.05
?? p<0.001
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β coefficient Hazard Ratio p-value †
Age at Diagnosis 0.000 1.00 0.072
Sex (Male) -0.022 0.98 0.085
Date of Diagnosis -0.253 0.78 0.108
Perianal Disease at Diagnosis -0.416 0.66 0.164
Smoking at Diagnosis -0.826 0.44 0.222
Smoking at OPO event 0.245 1.28 0.448
IV Steroids at Diagnosis 0.131 1.14 0.707
IL23R status (GG vs AG) 0.000 1.00 1.000
ATG16L1 status (Reference
Level A)
AG -0.161 0.85 0.710
G -0.825 0.44 0.102
Number of NOD2 Mutations
(Reference Level 0)
1 0.293 1.34 0.407
2 -0.521 0.59 0.479
Montreal Location at Diagnosis
(Reference Level L1)
L2 1.100 3.00 0.002 ?
L3 0.488 1.63 0.163
Table 6.5
Univariate cox regression: Other confounding variables.
† p-value for Log Rank test of association.
? p<0.05
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Haemoglobin (Sex Adjusted) <134 g L−1 (m)
<119 g L−1 (f)
Haemoglobin <135 g L−1
MCV <86 fL
Platelet Count >270 x109/L
White Cell Count >8.4 x109/L
Neutrophil Count >5.9 x109/L




Faecal Calprotectin >198 µg g−1
Ferritin <32 µg L−1
Iron <7 µmol L−1
Transferrin Saturation <11 %
Vitamin D <60 nmol L−1
Serum Folate <32 nmol L−1
Red Cell Folate <810 nmol L−1
Vitamin B12 <285 pmol L−1
Table 6.6
Optimal cutoff for conversion from continuous to categorical lvAUC variables.
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Odds Ratio p-value †
Albumin < 38 2.66 0.002 ?
CRP > 11 2.63 0.003 ?
Age < 32 3.86 0.005 ?
Montreal Location at Diagnosis
(reference level = L1)
L2 2.39 0.017 ?
L3 0.99 0.979
Table 6.7
Cox regression: Multivariate analysis
† Log Rank test
? p<0.05
?? p<0.001
Included Patients =263; Fistula events =47
No Fistula Fistula Sensitivity Specificity PPV NPV ? Duration Observation
† 0 38 0 7.6
1 111 13 1.00 0.18 0.21 1.00 7.5
2 52 18 0.72 0.69 0.34 0.92 7.3
3 14 11 0.34 0.93 0.52 0.87 6.1
4 1 5 0.11 1.00 0.83 0.84 2.1
Table 6.8
Contingency table.
† Number of predictors (CRP, albumin level, colonic disease location, age)
? Median value in years.
n=263
PPV=positive predictive value; NPV = negative predictive value.
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6.7. Discussion
In this study longitudinally measured serum albumin and CRP correlate with
subsequent development of perianal fistula in patients with Crohn’s disease. An
albumin consistently less than 38 g/L and a CRP consistently higher than 11 mg/L
were the cutoff levels most strongly correlated with perianal fistula development.
In addition to young age at diagnosis, complicated disease phenotype and colonic
location of disease,(Eglinton et al. 2012; Lapidus 2006) these variables may allow
further prediction of risk of perianal fistula formation, and allow more accurate
tailoring of preventative medical and/or surgical therapy.
In our experience laboratory testing for patients with Crohn’s disease tends to
be reactive, performed to correlate current symptoms with objective inflammatory
or nutritional markers, or to assess the response of these markers to a change in
therapy. This study demonstrates that these same laboratory variables can provide
an objective longitudinal assessment of inflammatory and nutritional status, an
assessment which correlates with the subsequent development of a perianal fistula.
It is noteworthy that the cut-off lvAUC values that were associated with perianal
fistula formation for these variables in our study were not markedly abnormal
when compared to normal ranges for individual results. Figure 6.4 demonstrates
that lvAUC is a markedly different entity to a single laboratory value, and that
only with consistent and significant abnormality in individual results is an lvAUC
value moved away from normality. lvAUC data cannot be compared to single
laboratory results, and must be considered without referring to to the normal
range for individual results.
Faecal calprotectin was used routinely in the management of our patients from
2008, and therefore a small number of observation periods had faecal calprotectin
data to use for analysis. There were not enough data, and not enough statis-
tical power, to adequately assess this biomarker, which may provide prognostic
information in future studies.
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6.7.1. Influence of diagnostic criteria
L2 location Crohn’s disease often requires disease location outside the ileum and
colon (perianal or upper GI involvement) to meet diagnostic criteria (Lennard-
Jones 1989) and distinguish it from ulcerative colitis. L1 and L3 location Crohn’s
disease do not rely on the presence of disease outside the ileum and colon to
meet diagnostic criteria. Because of this there is a selection bias associating L2
location with perianal disease. In this cohort all patients with perianal fistulae
within 9 months of diagnosis were excluded, meaning all patients with L2 disease
location met diagnostic criteria without the presence of perianal fistulae. Despite
this exclusion, there was still an association between subsequent perianal fistula
formation and colonic disease location. This temporal relationship between the
diagnosis of Crohn’s disease and subsequent perianal fistula formation provides
some evidence that colonic disease location is truly associated with perianal fistula
formation, and that this association is not the result of how diagnostic criteria are
defined.
L2 disease extent, young age at diagnosis and complex intestinal disease have
previously been published as predictors of development of perianal fistula forma-
tion or of perianal disease.(Eglinton et al. 2012; Rankin et al. 1979; Lapidus 2006;
D. R. Williams et al. 1981; Veloso et al. 2001; Tang, Rawsthorne, and Bernstein
2006) A consistently low albumin level and high CRP level are abnormalities that
would be expected to be associated with chronic inflammation. Patients who de-
veloped a perianal fistula in this study did not have significant perianal disease
prior to its development. These data suggest that perianal fistula formation is
more likely to occur in patients with chronic inflammation of the ileum or colon.
This interpretation of the data is consistent with the observation made by Eglinton
et al. that perianal disease is more common in patients with complex intestinal
disease.(Eglinton et al. 2012)
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6.7.2. Study weaknesses
This was an observational study and so was inherently subject to bias. We have
attempted to minimize bias through study design, although acknowledge that
unidentified bias may have influenced the observed associations.
42/91 of patients who developed a fistula were excluded from this analysis,
either because they developed a fistula early in their disease course, or because
no laboratory data were available prior to fistula development. This reduced the
statistical power of the study, and may have missed observing factors associated
with early fistula development. These problems are inherent in the study design,
which was structured to meet the primary aim of assessing the relationship between
longitudinal laboratory test results and subsequent perianal fistula formation.
It is possible there was delay between development of a perianal fistula and
its subsequent diagnosis. If this occurred with some frequency then this study
would be reduced to observing that low serum albumin and high serum CRP
are associated with active perianal disease. This possibility has been reduced by
excluding laboratory tests performed within the 3 months prior to fistula develop-
ment. Laboratory tests performed within 3 months of diagnosis were also excluded,
considering that there are a high number of complications in the months following
diagnosis, many of which are not immediately identified.
It is possible that the performance of abdominal surgery could confound the
relationship between laboratory results and subsequent perianal fistula formation.
Laboratory results taken within 3 months of abdominal surgery were excluded to
minimize this possibility.
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6.8. Conclusion
An albumin level consistently below 38 g/L or a CRP consistently above 11 mg/L
are associated with subsequent perianal fistula formation in patients with Crohn’s
disease. These laboratory results may provide additional prognostication of clinical
course for patients with Crohn’s disease, and allow better tailoring of preventative
therapy. These results require validation in an external cohort.
7. Further Longitudinal Analyses
We have accumulated a detailed longitudinal database on the RBWH cohort of
patients with Crohn’s disease. I have become very familiar with these data and
with methods of structuring and analyzing them in the statistical programming
environment R. This has led to a number of observations which we hope will yield
fruitful insight into the natural history of Crohn’s disease. Three of these analyses
are briefly outlined here.
The common thread which links these analyses to this thesis is that they all
interpret clinical questions through longitudinal analysis of objective data.
7.1. Longitudinal disease progression
Cosnes et al. published a paper describing the natural history of Crohn’s disease
in 2002 in Inflammatory Bowel Diseases, using the Vienna classification system.
(Cosnes, S. Cattan, et al. 2002; Gasche et al. 2000) This paper and others that
followed introduced the concept that Crohn’s disease is a chronic and progressive
disease, with patients moving from uncomplicated inflammatory disease to more
complicated disease (stricturing or penetrating) over time.
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Figure 7.1
Progressive Montreal phenotype, RBWH cohort
The same analysis, using the Montreal classification system, may be applied to
our cohort. (see figure 7.1) When this is done it demonstrates that in our cohort
long term disease outcome appears similar to that seen in the Saint-Antoine cohort
of Cosnes et al: a progression from inflammatory to stricturing to penetrating phe-
notype. It became apparent looking at our dataset that as time passed stricturing
complications occurred more commonly than penetrating complications. This led
to consideration as to why the Montreal classification system represents disease
progression in our cohort in this way.
The Montreal classification system classification describes disease progression
from inflammatory, to stricturing, to penetrating because it is defined to be hi-
erarchical and irreversible. A patient with a penetrating complication at any
timepoint in his or her disease course is classified as penetrating from that time
forward, regardless of what happens subsequently.
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We have considered classification of stenosing and penetrating complications in
our cohort in a slightly different way, removing the hierarchical and irreversible
aspects of the Montreal classification system as follows.
1. Classification at any one time-point is calculated from all complications that
occur in the 3 years prior to that timepoint.
2. Classification is not hierarchical. This means that four levels of classifica-
tion are necessary: Inflammatory, Stricturing, Penetrating, Stricturing and
Penetrating.
Using this classification, a rolling Montreal phenotype, it is evident that the
most commonly occurring complication in our cohort over time is stricture, and
that this is true regardless of what complications are observed in the first year of
disease course. (see figures 7.2, 7.3, 7.4, 7.5) The large change in all classification
at three years is due to the high proportion of patients who suffer a complication
at diagnosis, and then no further complication following this. Because of rolling
Montreal phenotype definition, this is observed 3 years after their last complication
- which was at or around the time of diagnosis.
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Figure 7.2
Rolling Montreal phenotype, RBWH cohort
Figure 7.3
Rolling Montreal phenotype, B1 phenotype within first year only, RBWH
cohort
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Figure 7.4
Rolling Montreal phenotype, B2 phenotype within first year only, RBWH
cohort
Figure 7.5
Rolling Montreal phenotype, B3 phenotype within first year only, RBWH
cohort
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7.2. Prediagnosis inflammatory signature
After matching laboratory data to our cohort we observed that many of the lab-
oratory tests obtained were taken before patients were diagnosed with Crohn’s
disease. There are published data suggesting that delay from reported onset of
symptoms to diagnosis of Crohn’s disease is in the order of 9 months.(Schoepfer,
Dehlavi, et al. 2013) Our laboratory data should provide a more objective marker
of disease activity prior to diagnosis. Is there a signature in blood testing per-
formed on patients prior to their diagnosis of Crohn’s disease, and how early is it
detectable?
This data was analyzed comparing results taken in the two years leading up to
diagnosis, considering results taken between two to three years prior to diagnosis
as a baseline. Date of diagnosis was assigned when the treating physician consid-
ered the patient to have Crohn’s disease and initiated treatment. This was usually
when endoscopy or imaging was performed to confirm the presence of bowel in-
flammation in the presence of chronic symptoms.
Many patients did not have blood testing performed prior to diagnosis. The
number of test results available for analysis are less than those available after di-
agnosis.
In this cohort there is a clear signal present in most blood tests that becomes
apparent 12 months prior to the date of diagnosis. Haemoglobin level and albumin
level begin to drop at this point, while platelet count, albumin level ESR and CRP
begin to rise. (see figures 7.6, 7.7, 7.8, 7.10, 7.9)
Chapter 7. Further Longitudinal Analyses 90
Figure 7.6
Prediagnosis laboratory signature: albumin
Figure 7.7
Prediagnosis laboratory signature: haemoglobin level
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Figure 7.8
Prediagnosis laboratory signature: platelet count
Figure 7.9
Prediagnosis laboratory signature: ESR
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Figure 7.10
Prediagnosis laboratory signature: CRP
Although these data are not useful for individual patients in the years leading
up to diagnosis, they do provide useful insight into prediagnostic inflammatory
bowel disease. These results agree with published data showing that clinical symp-
toms are present for 9 months prior to diagnosis in patients with Crohn’s disease.
(Schoepfer, Dehlavi, et al. 2013) They add additional weight to this finding in
that they are objective results, and are not subject to subjective patient recall of
duration of symptoms.
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7.3. Delay to meeting formal diagnostic cri-
teria in Crohn’s disease
There is a lack of consensus as to what criteria should be used to assign a patient
a diagnosis of Crohn’s disease. We feel our detailed longitudinal data provides
some insight into the process of diagnosing Crohn’s disease, through analysis of
the timecourse to meeting various diagnostic criteria.
What is Crohn’s disease? There is consensus that Crohn’s disease is an (often
granulomatous) transmural chronic inflammatory condition of the human gastroin-
testinal tract. Involvement may include segments of the gastrointestinal tract from
the mouth to the anus, and histologically it is characterized by submucosal in-
flammation, fibrosis and ulceration. In its original description Crohn’s disease was
considered a chronic inflammatory condition of the terminal ileum only. (Crohn
BB, Ginzburg L, and Oppenheimer GD 1932, see figure 7.11) In the 1960’s chronic
colonic inflammation with transmural features or presence of granulomata on histo-
logical specimen also came to be considered Crohn’s disease.(Lockhart-Mummery
and Morson 1960) Chronic inflammation of the oesophagus, stomach, duodenum,
jejunum and orobuccal mucosa also came to be recognized as part of the spec-
trum of Crohn’s disease, as they were often accompanied by disease typical of
Crohn’s disease in the ileum and colon. Formal diagnostic criteria were lacking
until Lennard-Jones proposed standardized criteria with which to assign a diag-
nosis of Crohn’s disease. (Lennard-Jones 1989, see table 3)
The European Crohn’s and Colitis Organization (ECCO) published a consensus
statement which includes a statement on the diagnosis of Crohn’s disease. (Van
Assche et al. 2010) These diagnostic criteria acknowledged that the Lennard-Jones
criteria often depend on a transmural surgical specimen to confirm a diagnosis of
Crohn’s disease. The ECCO diagnostic criteria attempt to provide clinical guid-
ance to allow a diagnosis of Crohn’s disease in the absence of a transmural surgical
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We propose to describe, in its pathologic and clinical details, a disease
of the terminal ileum, affecting mainly young adults, characterized by
a subacute or chronic necrotizing and cicatrizing inflammation. The
ulceration of the mucosa is accompanied by a disproportionate connec-
tive tissue reaction of the remaining walls of the involved intestine, a
process which frequently leads to stenosis of the lumen of the intes-
tine, associated with the formation of multiple fistulas.The disease is
clinically featured by symptoms that resemble those of ulcerative col-
itis, namely, fever, diarrhea and emaciation, leading eventually to an
obstruction of the small intestine; the constant occurrence of a mass in
the right iliac fossa usually requires surgical intervention (resection).
The terminal ileum is alone involved. The process begins abruptly at
and involves the ileocaecal valve in its maximal intensity, tapering off
gradually as it ascends the ileum orally for from 8 to 12 inches.....
Figure 7.11
From Regional ileitis: A pathologic and clinical entity Crohn et al, Journal of
the American Medical Association, 1932
specimen. However, in doing this they are less precise in how Crohn’s disease is
defined.
Research into all aspects of Crohn’s disease relies on a precise definition of the
condition. Lack of a precise definition leads to heterogeneity in research cohorts
of patients with Crohn’s disease, and less certainty that observations made in one
cohort of patients with Crohn’s disease are applicable to another cohort. Variation
between research cohorts in the proportion of patients with disease limited to the
colon could be considered one marker of this heterogeneity. In published cohorts
this proportion varies between 20% - 50%. (Loly, Belaiche, and Louis 2008; Tar-
rant et al. 2008; Magro et al. 2014; Lapidus 2006) We believe this heterogeneity
results from variation in interpretation of diagnostic criteria for Crohn’s disease.
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Figure 7.12
Cumulative incidence of complications, RBWH cohort
n=302
The current paradigm of medical management of Crohn’s disease is that chronic
bowel inflammation leads to irreversible tissue damage, and that therapy to con-
sistently suppress inflammation will prevent tissue damage. This approach to the
management of Crohn’s disease requires early implementation of therapy, before
the development of irreversible tissue damage. The provision of early therapy de-
pends on early diagnosis. Many of the complications seen in Crohn’s disease occur
within the first 6 months of diagnosis, as was observed in our cohort (see figure
7.12). We believe that neither the Lennard-Jones criteria nor the ECCO Consen-
sus Criteria are well designed to progress research in assessing the impact of early
medical intervention on the natural history of Crohn’s disease. The Lennard-Jones
criteria depend too heavily on the identification of evidence of a transmural disease
process to assign a diagnosis (a fistula, a stenosis or transmural histology obtained
from a surgical specimen). For many patients, by the time they meet Lennard-
Jones criteria for a diagnosis of Crohn’s disease, it is too late to implement therapy
to try to prevent these complications. In contrast, the ECCO Consensus Criteria
do allow assignment of a diagnosis of Crohn’s disease early in a patient’s disease
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course, without a surgical specimen. However, they are open to interpretation,
and if used to assign the diagnosis of Crohn’s disease in research cohorts, will lead
to further heterogeneity in patient populations.
In order to study the early disease course of Crohn’s disease, (natural history,
impact of medical or surgical therapy) diagnostic criteria for Crohn’s disease must
be clearly defined without requiring evidence of a transmural disease process. Al-
tering the diagnostic criteria for Crohn’s disease in this way would almost certainly
assign a diagnosis of Crohn’s disease to patients who by previous criteria would not
have received a diagnosis. However, research populations need to be transparently
defined in order to clearly assess natural history and response to therapy early in
their disease course.
Has there been a delay to meeting either Lennard-Jones criteria or ECCO Con-
sensus Criteria for a diagnosis of Crohn’s disease in our cohort? This information
will provide some insight into how current diagnostic criteria perform in the early
identification of patients with Crohn’s disease.
We consider that there are two main groups of patients who often do not meet
Lennard-Jones diagnostic criteria for Crohn’s disease early in their disease course.
One group are those patients with non-granulomatous disease isolated to the colon
without evidence of transmural complication. These patients are not able to be
clearly distinguished from patients with ulcerative colitis. The second group are
those with non-granulomatous disease isolated to the terminal ileum, without ev-
idence of transmural complication. For diagnostic purposes both groups need a
transmural histological specimen (a surgical specimen) to confirm or refute the
presence of submucosal ulceration or fibrosis. However, this information is not
available until a bowel resection is indicated, and performed. In our experience
the first group of patients will usually be advised to take appropriate therapy
whether they are considered to have Crohn’s disease, inflammatory bowel disease
type unspecified (IBD-TU) or ulcerative colitis. We observe that the second group
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of patients have a less clear disease trajectory, and physicians may be reluctant to
assign a diagnosis of Crohn’s disease and commit to immunomodulatory therapy
(and its side effects).
7.3.1. A brief description of methods
For this analysis the gold standard for a diagnosis of Crohn’s disease was consid-
ered to be meeting of the Lennard-Jones criteria within 5 years of diagnosis. We
restricted the analysis to these patients, and observed what at what time diagnos-
tic criteria were met. The date of diagnosis was the date on which the treating
physician felt a diagnosis of Crohn’s disease had been met, and therapy to treat
Crohn’s disease was initiated. This was usually when mucosal tissue was avail-
able for histological examination after ileocolonoscopy. The Lennard-Jones criteria
were considered met when 3 of the following criteria were present (2 if one was
granuloma): typical location, discontinuous macroscopic disease, transmural ulcer-
ation, transmural fibrosis, lymphocytic aggregation, and presence of granulomas.
The ECCO Consensus Criteria do not provide strict diagnostic criteria, and for
the purpose of this analysis only mucosal histological criteria were analyzed. The
ECCO histological criteria were considered met when 3 of the following criteria
(2 if one was granuloma) were present on mucosal biopsies or surgical specimens:
lymphocytic infiltrate, crypt architectural distortion, irregular villous architecture
(ileum), crypt abscesses, submucosal fibrosis, fissuring ulceration, and presence of
granulomas.
7.3.2. Results
This analysis demonstrates that 25% of the RBWH longitudinal cohort did not
meet the Lennard-Jones criteria for a diagnosis of Crohn’s disease within one year
of diagnosis, despite meeting these criteria over the next four years.(see figure 7.13)
This observation confirms that the Lennard-Jones criteria are too strict to allow
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Figure 7.13
Delay to fulfill Lennard-Jones criteria and ECCO histological criteria.
Analysis limited to patients who fulfilled the Lennard-Jones criteria within 5
years.
ECCO = European Crohn’s and Colitis Organization
early identification of a significant proportion of patients who definitely evolve
to have a transmural chronic inflammatory bowel condition. Further exploration
of these data should yield some insight into the characteristics of patients who
don’t meet the Lennard-Jones criteria early in their disease course. We may also
demonstrate how they may be identified through characteristics aside from the
Lennard-Jones criteria.
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Classification Systems in Crohn’s disease
Variable 0 1 2 3
Size of ulcers None Aphthous ulcers Large ulcers Very large ulcers
( 0.1 < θ < 0.5 cm) ( 0.5 < θ < 2 cm) (θ >2 cm)
Ulcerated surface None <10% 10-30% >30%
Affected surface Unaffected <50% 50-75% >75%
segment
Presence of None Single, Multiple, Cannot be passed
narrowings can be passed can be passed
Table 1
Simple endoscopic score - Crohn’s disease
θ = diameter
A score is calculated for each of five segments of the bowel: rectum, left colon,
transverse colon, right colon, ileum.
Total score is the sum of 5 segmental scores.
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Number of liquid or soft stools, each day, for seven days x 2
Abdominal pain I x 5
General well being † x 7
Presence of complications ? x 20
Taking medication to reduce diarrhoea x 30
Presence of an abdominal mass ( x 10
Haematocrit of <0.47 in men and <0.42 in women = x 6
Percentage deviation from standard weight ff x 1
Table 2
Crohn’s disease activity index. (Best et al. 1976)
I graded from 0-3 on severity each day, for seven days
† subjectively assessed from 0 (well) to 4 (terrible) each day, for seven days
? Score 20 for each complication: the presence of joint pains (arthralgia),
iritis, erythema nodosum, pyoderma gangrenosum, aphthous ulcers, anal
fissure, perianal fistula or abscess, other fistula, fever during the previous week.
( 0 none, 2 questionable, 5 definite
= × 6 for each 0.01 below cut-off value
Remission is a score <150





















Retention of colonic mucin on biopsy
Granulomata
Distinguished from caseating granulomata
Table 3
Lennard-Jones criteria for diagnosis of Crohn’s disease. (Lennard-Jones 1989)
Meeting 3 of inclusion features is suggested to confirm a diagnosis
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Age at diagnosis
A1 <16 years












p Perianal disease modifier
L4 Upper gastrointestinal involvement concurrent
with other disease location
Table 4








Organ Investigational na Segment Grade 1 Grade 2 Grade 3
Method
Surgical interventions
Upper tract 3 Esophagus Stomach — Bypass diversion or Resection
Duodenum stricturoplasty
Small bowel 20 Each 20-cm segment — Bypass diversion or Resection
stricturoplasty
Colon/Rectum 6 Each segment — Stomy, bypass diversion or Resection
stricturoplasty
Anus 1 Anus Reconstruction procedure, Major surgery leading to Definitive diversion
flap, coring out fistula track substantial sphincter Proctectomy
or laying open of fistula damageb
Temporary diversion
Stricturing lesions
Upper tract Endoscopy 3 Esophagus Stomach — Lumen narrowing, passable Stricture, nonpassable
Duodenum
MRI or CT 2 Stomach Wall thickening <3 mm Wall thickening ≥ 3mm or Stricture with prestenotic
Duodenum or segmental enhancement mural stratification without dilatation
without prestenotic prestenotic dilatation
dilatation
Small bowel MRI or CT 20 Each 20-cm segment Wall thickening <3 mm Wall thickening ≥ 3 mm or Stricture with prestenotic
or segmental enhancement mural stratification without dilatation
without prestenotic prestenotic dilatation
dilatation
Colon/Rectum Colonoscopy 6 Each segment — Lumen narrowing, passable Stricture, non passable
MRI or CT 6 Each segment Wall thickening <3 mm or Wall thickening ≥3 mm or Stricture with prestenotic
segmental enhancement mural stratification without dilatation or >50% of








dilatation <50% of the lumen
Anus Clinical 1 Anus Mild stricture Frank stricture, passable Frank stricture,
examination nonpassable
Penetrating lesions
Upper tract Endoscopy 3 Esophagus Stomach Superficial ulceration Deep ulceration Fistula
Duodenum
MRI or CT 2 Stomach — Deep transmural ulceration Phlegmon or any type
Duodenum of fistula
Small bowel MRI or CT 20 One 20-cm segment — Deep transmural ulceration Phlegmon or any type
of fistula
Colon/rectum Colonoscopy 6 Each segment Superficial ulceration Deep ulceration Fistula
MRI or CT 6 Each segment — Transmural ulceration Phlegmon or any type
of fistula
Anus Clinical 1 Anus Anal ulceration Multiple fistulae Multiple fistulae with
examination extensive anal and
perianal tissue
destruction
MRI or CTc 1 Anus Simple fistulad Branching fistula, multiple Extensive anal and perianal
fistulae, or any type of suppuration, horseshoe
abscess >1 cm abscess, or fistula(e)
involving or extending
above the levator plate
Table 5
The Lémann score; proposed severity score of irreversible tissue damage in patients with Crohn’s disease small bowel. (Pariente,
Mary, et al. 2015) aNumber of segments.
bDivision of the internal anal sphincter, external anal sphincter, or both for half or more of the length of the anal canal.
cOnly in case of abnormality at clinical examination.
dFistula extending from the anal canal to the perianal skin, but involving only the lowermost, or none, of the anal sphincter muscles,









Many variables used in these analyses were defined using automated algorithms
which took raw data from a database recording objective data, the longitudinal
Crohn’s disease database. This chapter summarizes these definitions which are
written in the statistical programming language “R”. The inclusion of this code is
intended to provide a precise definition of how variables were defined.
.1. Low level functions
These functions were defined to allow manipulation of observational data from the
longitudinal Crohn’s disease database. They are called in higher level functions
which define outcomes such as perianal fistula formation, or identification of bowel
stenosis.
1 fun_binary <-function(vector){
2 ##function to convert all NA strings to 0, and all numbers to 0 or 1, to allow








1 ##define ’sub_code function ’
2 sub_code <-function(path ,file){
3 ##’path ’ is PATH eg "home/james/cd/"
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4 ##’file ’ is filename to be run. It must be a .R file. The output will be saved as
.Rout in the same folder.
5 sink(paste(path ,file ,".Rout",sep=""))





This code calls subroutines into a master coding script. It allows simplified and
repetitive use of lower level functions and code snippetts in different analyses.
1 fun_make_relational <-function(a,b){
2 ##function for making a relational database for one investigation or set of
datapoints (for example surgeries , or abdominal radiology)
3 ##a=name of field to be used to grep columns (eg "^ Surgery", or "RadAbdo", or "^
Colo", or "^ PAClinical ")
4 ##b=name of database from which fields will be taken
5 ##colnames will be taken from cd database
6 fields <-colnames(b)[grep(a,colnames(b))]










17 for(i in 1:rep2){





23 out <-subset(out ,!is.na(out[,2]))
24 if(TRUE%in%(grepl("DateStart", names))){
25 out <-out[order(out[,grep("DateStart",names)],na.last=TRUE) ,]
26 }else if(TRUE%in%(grepl("Date", names))){
27 out <-out[order(out[,grep("Date",names)],na.last=TRUE) ,]
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Listing 3
Relational Conversion of Longitudinal Database.
The longitudinal Crohn’s Disease database is not in a relational format. This
following function converts data into relational format to allow further
analysis to occur with a simplified, relational data structure.
1 fun_numericFactor2text <-function(a,b,c){
2 ##function to convert to text description of levels
3 #a represents string to convert eg ’indicationsurgerystring ’ (double quotes)
4 #b represents field on which conversion will occur eg ’SurgeryInd ’ (double quotes
)













Conversion of Numeric coding to descriptive coding.
This function converts from numeric to descriptive strings, the conversion
vectors are contained in the master coding document “CD_coding.tex”. The
relationship between numbers and descriptive text is contained in the chapter
“Definition of Coding Strings” in the coding manual. Information coded by
descriptive strings is useful for production of graphs or tables.
1 fun_numericFactor2textstring <-function(a,b,c){
2 ##function to convert to text description of levels , for string fields
3 #a represents string to convert eg ’indicationsurgerystring ’ (double quotes)
4 #b represents field on which conversion will occur eg ’SurgeryInd ’ (double quotes
)
5 #c represents database eg ’cd’ (no quotes)
6 test <-strsplit(c[,b],split=",")
7 test <-list2df(test)
8 for (i in 1: length(colnames(test))){
9 test[,i]<-factor(test[,i])
10 test[,i]<-factor(test[,i],levels=sort(as.numeric(levels(test[,i]))))












Conversion of Numeric coding to descriptive coding: for string variables
.1.1. Grep functions
These functions are used to extract data from string variables. For example, on
a colonoscopy the extent of bowel involvement from anus to splenic flexure would
be coded "9,10,11" in the field ColoExtent. The following functions allow manipu-
lation of these strings to search for included coded integers. This allows a user to
ask questions such as “Is there ileal involvement on colonoscopy?”, or “Are there
granulomas on histology taken from colonic (not ileal) biopsy?”
.1.2. Strings for defining extent of bowel










11 ##as single string
12 grephisto.upper <-grepstring(c("4","4"))
13 grephisto <-grepstring(c("1","2","3","4","5","6","7"))















Definition of strings for defining particular bowel segments, or combinations of
other codes
.1.3. Calculation of bowel extent
These functions are used to calculate extent of disease, or of an abnormality (for eg.
a fistula) on any modality. fun_extent calculates simple extent of disease observed
on one type of procedure. How segments of bowel have been coded as involved
or uninvolved differs by modality (eg colonoscopy vs. radiological procedure) and
are documented in the coding manual. fun_extent_double allows more detailed
analysis, for example for colonscopy procedures which segments are involved with
granulomas present on histology, or which segments are involved microscopically
but not macroscopically.
1 fun_extentMaster <-function (...){
2 ##function to combine modalities for extent (eg: surgery , radiology and
colonoscopy)







Master function to combine extent calculated from different modalities
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1 fun_extent <-function(modality ,dateModality ,extentfield ,location ,dataframe ,date ,
add){
2 ##function to determine extent as observed by a modality (either surgery ,
radiology or colonoscopy. Output of this function will be combined at a later
point.
3 ##modality is name of relational dataframe eg < Colo > or < RadAbdo >
4 ##note that limiting of dataset to wanted investigations (eg only include
ileocolonoscopy and not flexible sigmoidoscopy) must be performed before
passing the dataframe to this function.
5 ##dateModality is the datefield in < modality >
6 ##extentfield is the field in which extent is recorded eg "RadAbdoExtent" or "
ColoExtent" or "ColoHistoMicroExtent"
7 ##location is location of interest eg colon , or ileum , or caecum: location is
either referred to as < grepcolo > or < grepileum >
8 ##dataframe is dataframe of patients being examined eg < cd > or < PRIME >
9 ##date is a date vector in < dataframe > which is the time -limit of this
definiton. Eg "DateDiag1" (date diagnosis) or "LstSeen" which is date of last
follow -up.
10 ##add is the time (in days) after < date > which serves as a cutoff - eg.
investigations performed within 180 days of diagnosis.
11 test <-!is.na(as.Date(modality[,dateModality ]))
12 tempMod <-subset(modality ,test)
13 test2 <-!is.na(as.Date(dataframe[,date]))
14 tempDF <-subset(dataframe ,test2)
15 l<-length(tempDF [,1])
16 out2 <-rep(NA ,l)
17 out3 <-rep(NA ,length(dataframe [,1]))
18 for(i in 1:l){
19 out <-as.list(rep(NA,length(location)))
20 test3 <-tempMod$id== tempDF$id[i] & as.Date(tempMod[,dateModality ]) <= (as.Date(
tempDF[i,date])+add)
21 temp <-subset(tempMod ,test3)
22 if(length(temp [,1]) >0){
23 for(j in 1: length(location)){
24 for(k in 1: length(temp [,1])){









34 for(m in 1: length(dataframe [,1])){
35 if(dataframe$id[m]%in%tempDF$id){
36 out3[m]<-out2[tempDF$id== dataframe$id[m]]






Calculation of extent of an abnormality on a single modality
1 fun_extent_double <-function(modality ,dateModality ,extentfield ,location ,
secondfield ,secondgrepstring ,dataframe ,date ,add){
2 ##function; same as fun_extent except:
3 ##secondfield is the field in which certain criteria need to be met (eg.
histological findings) before involvement is considered to be present.
Examples for this field are recorded eg "RadAbdoExtent" or "ColoExtent" or "
ColoHistoMicroCoded"
4 ##secondgrepstring; referred to as < grephisto > or similar. Must be a single
string , and not a vector of strings.
5 test <-!is.na(as.Date(modality[,dateModality ]))
6 tempMod <-subset(modality ,test)
7 test2 <-!is.na(as.Date(dataframe[,date]))
8 tempDF <-subset(dataframe ,test2)
9 l<-length(tempDF [,1])
10 out2 <-rep(NA ,l)
11 out3 <-rep(NA ,length(dataframe [,1]))
12 for(i in 1:l){
13 out <-as.list(rep(NA,length(location)))
14 test3 <-tempMod$id== tempDF$id[i] & as.Date(tempMod[,dateModality ]) <= (as.Date(
tempDF[i,date])+add)
15 temp <-subset(tempMod ,test3)
16 if(length(temp [,1]) >0){
17 for(j in 1: length(location)){
18 for(k in 1: length(temp [,1])){
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34 }
Listing 9
Calculation of extent of an abnormality on a single modality, with additional
restricting criteria
.1.4. Medication functions
This function defines medication use as the proportion of time taking the medi-
cation in the observation period preceding an outcome of interest. For example it
could state that azathioprine was taken for 46% of the time during the observation
period. It also generates the duration of the observation period in days.
1 fun_medication <-function(df.med ,type ,values ,datestart ,datestop ,df.outcome){
2 ##function calculates a representative number of exposure to a medication - 1
represents full exposure over the observation period , 0 represents no
exposure.
3 ##for eg: fun_medication(IS,c(1,2,6) ,"ISDateStart "," ISDateStop",outcome_full)
4
5 ##df.med is medication data frame of interest eg IS or FiveASA
6 ##type is datapoint recording type of medication (eg 6MP or AZA or MTX)
7 ##" values" is a vector of numeric codes of medications to include in the analysis
eg c(1,2,6) which are the thiopurines (see isstring_word)
8 ##" datestart" is date vector of the start date of the medication eg. "ISDateStart
"
9 ##" datestop" is the date vector of stop date of the medication eg. "ISDateStop"
10 ##df.outcome is the dataframe of outcomes - usually df.outcome is "outcome_full".





15 df.med2 <-subset(df.med ,test)
16 for(i in 1: length(df.outcome$id)){
17 id<-df.outcome$id[i]
18 t.test <-df.med$id==id
19 df.med3 <-subset(df.med2 ,t.test)
20 if(length(df.med3 [,1]) >0){
21 df.med3$mark <-NA
22 df.med3$mark <-ifelse(as.Date(df.med3[,datestart ])>as.Date(df.outcome$Date)[i]
| as.Date(df.med3[,datestop ])<as.Date(df.outcome$start)[i],0,1)
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23 df.med3$start <-ifelse(as.Date(df.med3[,datestart ])<as.Date(df.outcome$start)[
i],df.outcome$start[i],df.med3[,datestart ])
24 df.med3$stop <-ifelse(as.Date(df.med3[,datestop ])>as.Date(df.outcome$Date)[i],
df.outcome$Date[i],df.med3[,datestop ])
















.1.5. Laboratory variable processing
These functions are used to calculate a representative number for a laboratory
variable in the observation period preceding an outcome of interest. The code also
provides the duration of the observation period and the number of tests used to
calculate the number.
1 fun_AUC_vector <-function(df,lab ,lab_df,Area_function ,exclude_surg){
2 ##function to create a vector of modified AUC values during appropriate time
period for each outcome.
3 #df is dataframe being analysed eg. < outcome_full >, or <outcome_surgery >.
4 ##lab is laboratory variable of interest eg "PLT"
5 ##lab_df is name of dataframe in which variable sits eg. allHGB
6 ##Area function is either AUC1 or AUC2. AUC1 weighs towards lowest value (for
variables which are raised if patients are unwell/disease is active). AUC1
weighs towards highest value , for variables which drop as patients become
unwell.
7 ##exclude_surg; either true or false: if true then exclude all lab tests within "
surgery_cut" of an operation.
8 if(exclude_surg==TRUE){




12 lab_obs <-paste(lab ,"_obs",sep="")










22 include <-(as.Date(temp[,"collected"]) <(as.Date(df$Date[i])-observation_cut_
outcome) & (as.Date(temp[,"collected"])>as.Date(t.start)) & (as.Date(temp[,"
collected"])<as.Date(t.start)+observation_cut_end))
23 temp <-temp[include ,]
24 if(length(temp [,1]) >1 & !is.na(t.start) & !is.na(df$Date[i])){
25 temp <-temp[order(temp$collected) ,]











Master function to calculate area under curve of a laboratory variable
1 AUC <-function(a,b,c){
2 ##a is data of interest eg Platelet count "PLT"
3 ##b is date vector eg "collected"
4 ##c is dataframe
5 ##function calculates a rolling ’mean ’ of data , however instead of mean a value
val <-x+(y-x)/5 represents a middle value (x is the lower of the two values)
6 test <-!is.na(c[,a]) & !is.na(c[,b])
7 temp <-c[test ,]
8 l<-length(temp[,a])
9 if(l>1){
10 tmp <-rep(NA ,(l-1))
11 for (i in 2:l){
12 low <-min(as.numeric(temp[(i-1):i,a]))
13 high <-max(as.numeric(temp[(i-1):i,a]))
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14 val <-low+(high -low)/5
15 tmp[i-1] <-val
16 }
17 AUC <- sum(diff(as.numeric(as.Date(temp[,b])))*tmp ,na.rm=TRUE)








Area under curve of a laboratory variable: For variables that tend to rise with
inflammation
1 AUC2 <-function(a,b,c){
2 ##a is data of interest eg Platelet count "PLT"
3 ##b is date vector eg "collected"
4 ##c is dataframe
5 ##function calculates a rolling ’mean ’ of data , however instead of mean a value
val <-x+(y-x)/5 represents a middle value (x is the lower of the two values)
6 test <-!is.na(c[,a]) & !is.na(c[,b])
7 temp <-c[test ,]
8 l<-length(temp[,a])
9 if(l>1){
10 tmp <-rep(NA ,(l-1))
11 for (i in 2:l){
12 low <-min(as.numeric(temp[(i-1):i,a]))
13 high <-max(as.numeric(temp[(i-1):i,a]))
14 val <-low+4*(high -low)/5
15 tmp[i-1] <-val
16 }
17 AUC <- sum(diff(as.numeric(as.Date(temp[,b])))*tmp ,na.rm=TRUE)








Area under curve of a laboratory variable: For variables that tend to fall with
inflammation
1 fun_exclude_near_surgery <-function(a,cutoff_near_surgery){
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2 ##this function excludes lab results which occur near a surgery for each patient
(those with a TRUE in column 2$near_surgery are to be excluded).
3 ##a is dataframe eg allPLT
4 ##cutoff_near_surgery is the time period either side of a surgical event in days
(eg 30) in which lab data is not used.
5 ##this function uses the dataframe < Surgery > which includes all surgical
procedures regardless of what the indication or surgery type.
6 a$near_surgery <-rep(FALSE , length(a[,1]))
7 limit <-duplicated(Surgery$id)
8 t.Surgery <-subset(Surgery ,!limit)
9 for (i in 1: length(t.Surgery [,1])){
10 id<-t.Surgery[i,"id"]
11 test <-Surgery[,"id"]==id





17 mat <-matrix(data = NA, nrow = length(t.Surgery2 [,1]), ncol = length(t.a[,1]),
byrow = FALSE , dimnames = NULL)




21 out <-rep(NA ,length(t.a[,1]))
22 for(k in 1: length(t.a[,1])){








Exclusion of laboratory data around time of surgery
.1.6. Conversion of continuous to categorical variables
The following code automates a process to identify the value which is best used as a
cutoff to convert continuous to categorical variables. This value is selected compar-
ing the log rank of association by univariate cox regression between a categorical
Appendix B. Coding definitions 135
variable and the outcome of interest, using a varying cutoff. It also generates a
graphical representation of the calculation in .jpg format.
1 fun_cutoff_graph <-function(low ,high ,gap ,lab ,lablong1 ,lablong2){
2 ### function to dertmine optimal cutoff for converting continuous to categorical
variable
3 ##low is lower limit of cutoff to be examined
4 ##high is higer limit of cutoff to be examined
5 ##gap is the jump in value each iteration (eg < 1 > gives 13,14,15, < 0.1 > gives
13.1, 13.2, 13.3)
6 #lab is the name of the datapoint eg "ALB"
7 #lablong1 is the name of the datapoint for naming the file , and for the title of
the graph eg. "Albumin"
8 #lablong2 is appropriate descriptor of < lablong > eg "Count", or "Level"
9 test <-seq(low ,high ,by=gap)
10 temp <-data.frame(lab_value=character (),
11 LogRank=character (),
12 stringsAsFactors=FALSE)
13 for (i in 1: length(test)){
14 coxfit <-NA
15 outcome_full$temp <-ifelse(outcome_full[,lab]<test[i],1,0)
16 coxfit <-coxph(Surv(outcome_full$surv ,outcome_full$event)~ temp , data=outcome_full
)
17 temp2 <-c(test[i],coxfit$score)










28 plot(temp[,1:2],col=’blue’,type=’l’,main=paste("Continous to Categorical: \






Calculation of optimal cutoff for conversion of continuous to categorical
variables
1 fun_sig_cox_univariate2 <-function(coxfit){
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2 ##function to display significance of log.rank test for univariate analysis)








Display of univarite cox regression analysis
1 fun_sig_cox_univariate_multilevel <-function(coxfit){
2 ##function to display significance of log.rank test for univariate analysis)




7 t.coefficient <-paste("coefficients",t.n.vec ,sep="")
8 t.out <-matrix(rep(NA ,(t.n-1)*5),nrow=(t.n-1),ncol =5)










Display of univarite cox regression analysis, for regression using mulitlevel
categorical variables
.2. Montreal disease classification
The following functions define Montreal Disease Classification at a given time-
point in the disease course - For eg. at diagnosis, or at time of first surgery, or
last follow-up.
1 fun_montreal_location <-function(a,b){
2 ##function to determine extent
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3 ##dataframe is dataframe in which vectors reside
4 ##a = ileal extent vector eg "extent.ileal.dx"







Daughter function to calculate disease location as defined by the Montreal
Classification System
1 ##montreal classification function
2 montreal_location <-function(Datefield ,locationCutoff){
3 ##locationCutoff is the time in days after the date at which location is being
determined in which it is permissible to use location data (eg a colonoscopy
6 months after diagnosis).
4 ##suffix is the suffix to add to all colnames for this montreal classification -
either ".dx" ".LFU" or something else depending on timepoint.
5
6 ##ileal extent at date.
7 t.rad <-fun_extent(RadAbdo2 ,"RadAbdoDate","RadAbdoExtent",grepsmallbowel ,cd,
Datefield ,locationCutoff)
8 t.colo <-fun_extent(Colo ,"ColoDate","ColoExtent",grepsmallbowel ,cd ,Datefield ,
locationCutoff)
9 t.colo.hist <-fun_extent_double(Colo ,"ColoDate","ColoHistoMicroExtent",
grepsmallbowel ,"ColoHistoMicroCoded",grephisto ,cd,Datefield ,locationCutoff)
10 t.surg <-fun_extent_double(Surgery2 ,"SurgeryDate","SurgHistoMicroExtent",
grepsmallbowel ,"SurgeryHistoMicroCoded",grephisto ,cd,Datefield ,locationCutoff
)
11 location.ileal <-fun_extentMaster(t.rad ,t.colo ,t.surg)
12
13 ##colonic extent at date.
14 t.rad <-fun_extent(RadAbdo2 ,"RadAbdoDate","RadAbdoExtent",grepcolo ,cd,Datefield ,
locationCutoff)
15 t.colo <-fun_extent(Colo ,"ColoDate","ColoExtent",grepcolo ,cd,Datefield ,
locationCutoff)
16 t.colo.hist <-fun_extent_double(Colo ,"ColoDate","ColoHistoMicroExtent",grepcolo ,"
ColoHistoMicroCoded",grephisto ,cd,Datefield ,locationCutoff)
17 t.surg <-fun_extent_double(Surgery2 ,"SurgeryDate","SurgHistoMicroExtent",grepcolo ,
"SurgeryHistoMicroCoded",grephisto ,cd ,Datefield ,locationCutoff)
18 location.colo <-fun_extentMaster(t.rad ,t.colo ,t.surg)
19 location.montreal <-fun_montreal_location(location.ileal ,location.colo)
20
21 print(paste("Location Data from longitudinal database at < datefield > timepoint
- L0 means no evidence of bowel involvement on imaging/endoscopy/surgery",sep
=" "))
















Master function to calculate disease location as defined by the Montreal
Classification System
1 fun_montreal_behaviour <-function(dataframe ,a,b){
2 ##function to determine behaviour
3 ##dataframe is dataframe in which vectors reside
4 ##a = perforation vector







Daughter function to calculate disease behaviour as either inflammatory,
stricturing or penetrating, or penetrating and stricturing.
1 ##montreal classification function
2 montreal_behaviour <-function(Datefield ,Cutoff){
3 ##datefield is the time when analysis is to be made eg "LstSeen" or "DateDiag"
4 ##Cutoff is the time in days after the date at which location is being determined
in which it is permissible to use location data (eg a colonoscopy 6 months
after diagnosis).
5 ##suffix is the suffix to add to all colnames for this montreal classification -
either ".dx" ".LFU" or something else depending on timepoint.
6
7 ##penetrating disease at lfu. (abcess , fistula)
8 t.rad <-fun_extent(RadAbdo2 ,"RadAbdoDate","RadAbdoFist",grepbowel ,cd,Datefield ,
Cutoff)
9 t.rad2 <-fun_extent(RadAbdo2 ,"RadAbdoDate","RadAbdoOther",grepabcessRad ,cd,
Datefield ,Cutoff)
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10 t.colo <-fun_extent(Colo ,"ColoDate","ColoFist",grepbowel ,cd,Datefield ,Cutoff)
11 t.surg1 <-fun_extent(Surgery2 ,"SurgeryDate","SurgeryFist",grepbowel ,cd,Datefield ,
Cutoff)
12 t.surg2 <-fun_extent(Surgery2 ,"SurgeryDate","SurgeryOther",grepabcessSurg ,cd ,
Datefield ,Cutoff)
13 t.surg3 <-fun_extent(Surgery2 ,"SurgeryDate","SurgeryPerf",grepabcessSurg ,cd,
Datefield ,Cutoff)
14 t.pen <-fun_extentMaster(t.rad ,t.rad2 ,t.colo ,t.surg1 ,t.surg2 ,t.surg3)
15 t.pen <-fun_binary(t.pen)
16
17 ##stenosis at lfu.
18 t.rad <-fun_extent_double(RadAbdo2 ,"RadAbdoDate","RadAbdoStenosis",grepbowel ,"
RadAbdoStenosisDilation",grepDilation ,cd ,Datefield ,Cutoff)
19 t.colo <-fun_extent(Colo ,"ColoDate","ColoStenosis",grepbowel ,cd,Datefield ,Cutoff)
20 t.surg <-fun_extent(Surgery2 ,"SurgeryDate","SurgeryStenosis",grepbowel ,cd,
Datefield ,Cutoff)
21 t.sten <-fun_extentMaster(t.rad ,t.colo ,t.surg)
22 t.sten <-fun_binary(t.sten)
23
24 ##montreal at lfu.




Master function to calculate disease behaviour as either inflammatory,
stricturing or penetrating, or penetrating and stricturing. This is similar to
the Montreal Classification System
1 ##montreal classification function
2 montreal_perianal_modifier <-function(Datefield ,locationCutoff){
3 ##locationCutoff is the time in days after the date at which location is being
determined in which it is permissible to use location data (eg a colonoscopy
6 months after diagnosis).
4 ##suffix is the suffix to add to all colnames for this montreal classification -
either ".dx" ".LFU" or something else depending on timepoint.
5 ##perianal disease at date
6 t.PAclin <-fun_extent(PAclinical ,"PAClinicalDate","PAClinicalFistula",grepfistula ,
cd,Datefield ,locationCutoff)
7 t.PArad <-fun_extent(RadPA ,"RadPADate","RadPAFistula",grepfistula ,cd,Datefield ,
locationCutoff)
8 t.PAsurg.fist <-fun_extent(PASurgery ,"PASurgeryDate","PASurgeryFistula",
grepfistula ,cd,Datefield ,locationCutoff)
9 #t.PAsurg.abcess <-fun_extent(PASurgery ," PASurgeryDate "," PASurgeryAbcess",
grepabcess ,cd,Datefield ,locationCutoff)
10 t.PA<-fun_extentMaster(t.PAclin ,t.PArad ,t.PAsurg.fist)
11 t.PA<-ifelse(t.PA >0,1,0)




Master function to calculate perianal disease modifier as defined by the
Montreal Classification System
1 ##montreal classification function
2 montreal_upperGI_modifier <-function(Datefield ,locationCutoff){
3 ##locationCutoff is the time in days after the date at which location is being
determined in which it is permissible to use location data (eg a colonoscopy
6 months after diagnosis).
4 ##suffix is the suffix to add to all colnames for this montreal classification -
either ".dx" ".LFU" or something else depending on timepoint.
5 ##perianal disease at date
6 t.upper.hist <-fun_extent_double(Gas ,"GastroDate","GastroHistoMicroExtent",
grepupper ,"GastroHistoMicroCoded",grephisto.upper ,cd,Datefield ,locationCutoff
)
7 t.temp <-fun_extentMaster(t.upper.hist)




Master function to calculate upper GI disease modifier as defined by the
Montreal Classification System
.3. Fistula, stenosis or perforation occurence
The definition of occurence of intestinal fistula, stenosis or perforation (outcome) is
defined here. This definition is made based on data from colonoscopy, gastroscopy,
radiological procedures, surgery, histology from surgical specimens, and clinical
examination events. There are multiple observations by multiple modalities of
outcomes (eg. on CT, colonoscopy, at surgery). This code makes an assessment
as to whether observed outcomes are repeat observations of previously observed
outcomes, or if they are observations of a new outcome.
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.3.1. Time cutoffs
These cutoffs are the time periods used to distinguish whether an observed out-
come is a repeat observation of a previously observed outcome, or is a new outcome.
1
2 ##cutoff_passive_independence: cutoff in days for measuring whether an outcome
event is new , or if it is observation of a previously observed outcome event.
3 cutoff_passive_independence <-730
4
5 ##cutoff_surgical_independence: cutoff in days for measuring whether an event is
new , or if it is observation of a previously observed outcome which has not
been resolved by intervening surgery. This cutoff may be shorter than passive




8 ##passive resolution_cutoff: cutoff in days for measuring whether an event has
resolved. This time must pass without observation of the outcome for it to be
considered passively resolved. If the outcome is observed again (one or more
times) then ’passive_resolution_cutoff ’ must then pass from the latest date
it was observed , for the outcome to be considered resolved.
9 passive_resolution_cutoff <-cutoff_passive_independence
10
11 ##surgical resolution_cutoff: cutoff in days for measuring whether an event has
resolved. This time must pass without observation of the outcome , after
surgery resecting the affected bowel , for the outcome to be considered
surgically resolved. If the outcome is observed again (one or more times)
then ’passive_resolution_cutoff ’ must pass from the latest date it was
observed , for the outcome to be considered resolved.
12 surgical_resolution_cutoff1 <-cutoff_surgical_independence
Listing 24
Cutoff definitions used to define indepedence of observed outcomes
.3.2. Master code to process definition
The output of this code is a table with a line for each outcome. There may be
multiple lines per patient. To allow regression analysis a line is added for patients
who have not suffered an outcome at the end of the study period. This added
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line has “no outcome, censored” as the identified outcome and will be used as a
censored event in analysis.
1 ##now create outcome table
2 ##create outcome dataframes for individual endpoints (possibly multiple per






















24 ##create full outcome dataframe
25 sub_code(path_in ,"outcome_full")
26
27 ##remove temp files (those starting with ’t.’ and ’tt.’)
28 rm(list=ls()[grepl("^t\\.",ls())])
Listing 25
Master code to calculate when independent fistulae, perforations or stenoses
occur. Those that are observed within a certain time of a previously observed
event are considered a repeat observation of the same event and treated as
such.
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.3.3. Independent fistula or stenosis occurrence
This code outputs a table with one line per row for each independent event (eg.
Fistula). Only one type of event is analyzed. There may be multiple lines per
patient. It can calculate “Fistula” and “Stenosis” but not “Perforation”. “Perfora-
tion” is coded by “outcome_abcess_perf”. Perforation, fistula and stenosis events
are then combined into one table using the code “outcome_full”.
1 ## ’out ’ is the boolean vector which describes whether outcome has been met in
observed procedure
2 ##modality is the modality of the observing procedure
3




8 t.allNames <-c(t.coloNames ,t.radNames ,t.surgNames)
9
10 tt.out <-t.allNames[grepl(obs ,t.allNames)]
11 tt.date <-t.allNames[grepl("Date",t.allNames)]





16 ##define colnames of outvector
17 ##LocString is location of outcome eg. ’6,7’ (terminal ileum and caecum).
18 t.outNames <-c("id","Date","LocString","out","modality")
19
20 ##clean outcome field of interest (no 1’s)
21 #note will need to review fields in this coding at a later date.
22 ##change 1 to 0 if it exists on it’s own in stenosis strings (likely coding error









28 ##(merge all modalities)
29 #########################
30 #RadAbdo2
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34 Colo$out <-ifelse(!(Colo[,t.coloNames%in%tt.out ]==0 | is.na(Colo[,t.coloNames%in%
tt.out]) | grepl("[a-zA -Z]",Colo[,t.coloNames%in%tt.out])) ,1,0)
35 Colo$modality <-"colonoscopy"
36 #Surgery2
37 Surgery2$out <-ifelse(!(Surgery2[,t.surgNames%in%tt.out ]==0 | is.na(Surgery2[,t.





41 ##select columns of interest only and give them unifying names
42 #########################
43 #define function
44 unify <-function(f.string ,f.names ,f.table.original){
45 ##f.string -> string on which to search attributes columns to identify which
table they are in.
46 ##f.names -> string of columnnames of the table to be modified eg "t.surgNames"
47 ##f.table -> name of temporary table to be created eg t.Surgery2
48 ##f.table2 -> name of original table eg Surgery2
49 t.test <-!grepl(f.string ,attribute)
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73
74 t.Surgery2 <-unify("Surg",t.surgNames ,Surgery2)
75 t.RadAbdo2 <-unify("Rad",t.radNames ,RadAbdo2)
76 t.Colo <-unify("Colo",t.coloNames ,Colo)
77








86 ##if outcome is STENOSIS:
87 #########################
88 # #1 Seperate into multiple rows where more than one stenosis exists.
89 # #2 Additionally remove anal stenosis from this analysis (at a later point
these could be moved to PAclinical field).
90 # #3 Recode as no stenosis if ’attribute ’ (stenosis_dilation) <2.5cm
91 # #4 Remove lines where a second stenosis has been observed on the same





96 t.temp <-tt.outcome[t.mult ,]
97 for(i in 1: length(t.temp [,1])){
98 t.temp2 <-strsplit(t.temp$LocString[i],",")
99 t.temp3 <-strsplit(t.temp$attribute[i],",")
100 t.len <-length(t.temp2 [[1]])
101 t.temp4 <-t.temp[rep(i, each=t.len) ,]
102 t.temp4[,"LocString"]<-t.temp2
103 t.temp4[,"attribute"]<-t.temp3
104 t.temp <-rbind(t.temp ,t.temp4)
105 }
106 t.temp <-t.temp[!grepl(",",t.temp$LocString),]






112 tt.outcome$out <-ifelse(tt.outcome$modality =="radiology" & (is.na(tt.outcome$
attribute) | tt.outcome$attribute <2.5) ,0,tt.outcome$out)
113 #4
114 tt.outcome <-tt.outcome[!duplicated(paste(tt.outcome$Date ,tt.outcome$id ,tt.outcome
$LocString)) ,]
115 }
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116
117 #########################
118 ##if outcome is FISTULA:
119 #########################
120 ##remove attribute (fistulae do not have an attribute)
121 tt.outcome$attribute <-NA
122




127 ##identify outcomes which qualify as independent outcome events , observed on
radiology , colonoscopy or surgery.
128 #########################
129
130 # An old outcome is one that has been identified previously on radiology ,
colonoscopy or at surgery , prior to time period defined by ’cutoff_passive_
independence ’ and ’cutoff_surgical_independence ’.
131 # A recent outcome is one identified within time period before the outcome
being assessed (as defined by ’cutoff_passive_independence ’ and ’cutoff_
surgical_independence ’).
132 # ’cutoff_passive_independence ’ is used to assess whether most prior outcomes are
’old ’ or ’recent ’.
133 # If a prior outcome is surgical resection of affected segment ,’cutoff_surgical_
independence ’ is used to assess whether it is ’old ’ or ’recent ’.( this cutoff
is shorter , acknowledging that surgery usually resolves stenosis/fistulae).
134 # If no recent outcome exists then the outcome being assessed is considered
independent.
135









145 for (i in 1: length(cd[,1])){
146 id<-cd$id[i]
147 t.temp <-tt.outcome[tt.outcome$id==id ,]
148 t.temp <-t.temp[order(t.temp$Date),]
149 if(length(t.temp [,1]) >0){
150 t.temp$outcome <-NA
151 t.temp[1,"outcome"]<-t.temp$out[1]
152 if(length(t.temp [,1]) >1){
153 for (j in 2: length(t.temp [,1])){
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154 ##in the ’cutoff_surgical_independence ’ period before this test , was an outcome
observed? (whether or not there has been intervening surgery).
155 t.compareAll <-subset(t.temp ,as.Date(t.temp$Date[j])-as.Date(t.temp$Date)<cutoff_
surgical_independence & as.Date(t.temp$Date[j])-as.Date(t.temp$Date) > 0 & t.
temp$out ==1)
156 ##in the period between ’cutoff_passive_independence ’ and ’cutoff_surgery_
independence ’ before this test , was an outcome which was not "surgery
resecting involved segment" observed? (If it is a surgical resection in this
time period it is considered ’old ’, otherwise it is considered recent).
157 t.comparePassive <-subset(t.temp ,as.Date(t.temp$Date[j])-as.Date(t.temp$Date)<
cutoff_passive_independence & as.Date(t.temp$Date[j])-as.Date(t.temp$Date) >=
cutoff_surgical_independence & t.temp$out ==1 & (!t.temp$modality =="surgery"
| grepl(t.temp$LocString[j],t.temp$attribute2)))
158 ##code only independent outcomes as ’1’ in
159 t.temp$outcome[j]<-ifelse(t.temp$out[j]==0 | length(t.compareAll [,1]) >0 | length(
t.comparePassive [,1]) >0,0,1)
160 }}}
161 t.temp2 <-subset(t.temp ,t.temp$outcome ==1)
162 tt.outcome2 <-rbind(tt.outcome2 ,t.temp2)
163 }
164 tt.outcome2$outcomeID <-c(1: length(tt.outcome2 [,1]))
165






172 ##definition of resolution of outcome:
173 ##subsequent surgery resecting affected segment of bowel within ’surgical_
resolution_cutoff ’; or
174 ##Once "passive_resolution_cutoff ’ time has passed without recurrent observation
of stenosis.
175
176 ##add colnames needed for resolution data.
177 t.resolutionNames <-c("DateResolution","resolution","SurgeryLocResolution")




182 for (i in tt.outcome2$outcomeID){
183 ##reset resolution vector to NA
184 t.resolution <-NA
185 ##id of patient for this outcome event
186 t.id<-tt.outcome2$id[tt.outcome2$outcomeID ==i]
187 ##isolate outcome event
188 t.out <-tt.outcome2[tt.outcome2$outcomeID ==i,]
189 t.temp <-tt.outcome[tt.outcome$id==t.id ,]
Appendix B. Coding definitions 148
190
191 #determine date of resolution (passive or surgical)
192 ##resMarker: 1 means that this investigation demonstrates that the outcome being
observed has not yet resolved: 0 means that it has resolved (over <
passive_resolution_cutoff > has passed without observation of outcome).




196 t.len <-length(t.passRes [,1])
197 ##if surgery was affected segment removed?
198 t.rightLoc <-rep(NA ,length(t.passRes [,1]))
199 t.grep <-(grepstringvector(t.passRes$attribute2))




204 t.passRes$resMarker [1] <-1
205 if (length(t.passRes [,1]) >1){
206 for (j in 2: length(t.passRes [,1])){
207 ##if preceding examintion resection of affected segment , use < surgical_
resolution_cutoff1 > otherwise use < passive_resolution_cutoff >





213 ##if t.cutoff hasn ’t passed , mark resMarker < 1 >.






219 ##mark resMarker2 as < 1 > for the last investigation that observes the
unresolved outcome.
220 t.passRes$resMarker2 <-NA
221 for (j in 2: length(t.passRes [,1])){




226 ##for the last observation , mark resMarker2 as < 1 > if patient has been
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230 ##if last examintion is resection of affected segment , use < surgical_
resolution_cutoff1 > otherwise use < passive_resolution_cutoff >





236 ##mark resMarker2 as < 1 > for the last investigation if patient has been





240 ##select resolution observation ( where resMarker2 = 1 )
241 t.resolution <-subset(t.passRes ,!is.na(t.passRes$resMarker2)&t.passRes$
resMarker2 ==1)
242 ##assign date of resolution (after appropriate resolution cutoff period has
passed).
243 if(length(t.resolution [,1]) >0){
244 t.resolution <-t.resolution[,c("Date","modality","attribute2")]




247 t.resolution <-c(t.end ,"no_resolution",NA)
248 }
249 }
250 ##above nested code assigns resolution where more than one observation exists
after the initial observation. For those with only the initial observation ,
code below assigns resolution dependant on whether < resolution cutoff > has
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268
Listing 26
Code = “Outcome”. Definition of Independent Occurence of Fistula or Stenosis
.3.4. Independent perforation or abcess occurrence
This code outputs a table with one line per row for each independent perforation
event. There may be multiple lines per patient. Perforation, fistula and stenosis
events are then combined into one table using the code “outcome_full”.
1
2 ## ’out ’ is the boolean vector which describes whether outcome has been met in
observed procedure
3 ##modality is the modality of the observing procedure
4
5 #create vector of column names of three observation dataframes
6 t.radNames <-colnames(RadAbdo2)
7 t.surgNames <-colnames(Surgery2)









16 ##define colnames of outvector




21 ##(merge all modalities)
22 #########################
23 #RadAbdo2 (perforation or abcess on this exam? c(1,2))
24 grepperfstring_Rad <-grepstring(c(1,2))




28 #Surgery (note need to clean this string , there are a number of ’1’s recorded.
29 grepperfstring_Surg <-grepstring(c(1,4,5,6,7,8,9,10,11,13))
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30 grepabcessstring_Surg <-grepstring(c(2,6))





35 ##select columns of interest only and give them unifying names
36 #########################
37 #define function
38 unify <-function(f.string ,f.names ,f.table.original){
39 ##f.string -> string on which to search attributes columns to identify which
table they are in.
40 ##f.names -> string of columnnames of the table to be modified eg "t.surgNames"
41 ##f.table -> name of temporary table to be created eg t.Surgery
42 ##f.table2 -> name of original table eg Surgery
43 t.test <-!grepl(f.string ,attribute)

























68 t.Surgery2 <-unify("Surg",t.surgNames ,Surgery2)
69 t.RadAbdo2 <-unify("Rad",t.radNames ,RadAbdo2)
70 t.RadAbdo2 <-t.RadAbdo2[,c(1:3 ,3 ,4:7)]
71 t.RadAbdo2 [,3]<-NA
72 t.outNames2 <-c(t.outNames ,"attribute","attribute2")
73 colnames(t.Surgery2)<-t.outNames2
74 colnames(t.RadAbdo2)<-t.outNames2
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75 tt.outcome <-rbind(t.Surgery2 ,t.RadAbdo2)
76 tt.outcome <-tt.outcome[!is.na(tt.outcome$Date),]
77




82 ##identify outcomes which qualify as independent outcome events , observed on
radiology , colonoscopy or surgery.
83 #########################
84
85 # An old outcome is one that has been identified previously on radiology ,
colonoscopy or at surgery , prior to time period defined by ’cutoff_passive_
independence ’ and ’cutoff_surgical_independence ’.
86 # A recent outcome is one identified within time period before the outcome
being assessed (as defined by ’cutoff_passive_independence ’ and ’cutoff_
surgical_independence ’).
87 # ’cutoff_passive_independence ’ is used to assess whether most prior outcomes are
’old ’ or ’recent ’.
88 # If a prior outcome is surgical resection of affected segment ,’cutoff_surgical_
independence ’ is used to assess whether it is ’old ’ or ’recent ’.( this cutoff
is shorter , acknowledging that surgery usually resolves stenosis/fistulae).
89 # If no recent outcome exists then the outcome being assessed is considered
independent.
90









100 for (i in 1: length(cd[,1])){
101 id<-cd$id[i]
102 t.temp <-tt.outcome[tt.outcome$id==id ,]
103 t.temp <-t.temp[order(t.temp$Date),]
104




109 if(length(t.temp [,1]) >1){
110 for (j in 2: length(t.temp [,1])){
111 ##in the ’cutoff_surgical_independence ’ period before this test , was an outcome
observed? (whether or not there has been intervening surgery).
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112 t.compareAll <-subset(t.temp ,as.Date(t.temp$Date[j])-as.Date(t.temp$Date)<cutoff_
surgical_independence & as.Date(t.temp$Date[j])-as.Date(t.temp$Date) > 0 & t.
temp$out ==1)
113
114 ##in the period between ’cutoff_passive_independence ’ and ’cutoff_surgery_
independence ’ before this test , was an outcome which was not "surgery
resecting involved segment" observed? (If it is a surgical resection in this
time period it is considered ’old ’, otherwise it is considered recent).
115 t.comparePassive <-subset(t.temp ,as.Date(t.temp$Date[j])-as.Date(t.temp$Date)<
cutoff_passive_independence & as.Date(t.temp$Date[j])-as.Date(t.temp$Date) >=
cutoff_surgical_independence & t.temp$out ==1 & !t.temp$modality =="surgery")
116 ##code only independent outcomes as ’1’ in
117 t.temp$outcome[j]<-ifelse(t.temp$out[j]==0 | length(t.compareAll [,1]) >0 | length(
t.comparePassive [,1]) >0,0,1)
118 }}}
119 t.temp2 <-subset(t.temp ,t.temp$outcome ==1)
120 tt.outcome2 <-rbind(tt.outcome2 ,t.temp2)
121 }
122 tt.outcome2$outcomeID <-c(1: length(tt.outcome2 [,1]))
123






130 ##definition of resolution of outcome:
131 ##subsequent surgery resecting affected segment of bowel within ’surgical_
resolution_cutoff ’; or
132 ##Once "passive_resolution_cutoff ’ time has passed without recurrent observation
of stenosis.
133
134 ##add colnames needed for resolution data.
135 t.resolutionNames <-c("DateResolution","resolution","SurgeryLocResolution")




140 for (i in tt.outcome2$outcomeID){
141 ##reset resolution vector to NA
142 t.resolution <-NA
143 ##id of patient for this outcome event
144 t.id<-tt.outcome2$id[tt.outcome2$outcomeID ==i]
145 ##isolate outcome event
146 t.out <-tt.outcome2[tt.outcome2$outcomeID ==i,]
147 t.temp <-tt.outcome[tt.outcome$id==t.id ,]
148
149
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150 #determine date of resolution (passive or surgical)
151 ##resMarker: 1 means that this investigation demonstrates that the outcome being
observed has not yet resolved: 0 means that it has resolved (over <
passive_resolution_cutoff > has passed without observation of outcome).




155 t.len <-length(t.passRes [,1])
156 ##if surgery was affected segment removed?
157 t.passRes$resMarker <-NA
158 t.passRes$resMarker [1] <-1
159 if (length(t.passRes [,1]) >1){
160 for (j in 2: length(t.passRes [,1])){
161 ##if preceding examintion resection of affected segment , use < surgical_






167 ##if t.cutoff hasn ’t passed , mark resMarker < 1 >.






173 ##mark resMarker2 as < 1 > for the last investigation that observes the
unresolved outcome.
174 t.passRes$resMarker2 <-NA
175 for (j in 2: length(t.passRes [,1])){




180 ##for the last observation , mark resMarker2 as < 1 > if patient has been




184 ##if last examintion is resection of affected segment , use < surgical_
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190 ##mark resMarker2 as < 1 > for the last investigation if patient has been





194 ##select resolution observation ( where resMarker2 = 1 )
195 t.resolution <-subset(t.passRes ,!is.na(t.passRes$resMarker2)&t.passRes$
resMarker2 ==1)
196 ##assign date of resolution (after appropriate resolution cutoff period has
passed).
197 if(length(t.resolution [,1]) >0){
198 t.resolution <-t.resolution[,c("Date","modality","attribute2")]




201 t.resolution <-c(t.end ,"no_resolution",NA)
202 }
203 }
204 ##above nested code assigns resolution where more than one observation exists
after the initial observation. For those with only the initial observation ,
code below assigns resolution dependant on whether < resolution cutoff > has



















Code = “outcome_abcess_perf”. Definition of Independent Occurence of
Perforation
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.3.5. Merging of fistula, stenosis or perforation events
This code combines seperate tables made for fistulae, perforation events and steno-
sis events, and combines them into one outcome table. Where different events
(fistula and stensis for eg.) occur at the same time, they are combined into a
“combination” event.








7 outcome <-outcome[order(outcome$id,outcome$Date ,outcome$DateResolution) ,]
8 table(outcome$id)
9







16 temp[,cols [4: length(cols)]]<-NA
17 temp$outcome <-"no_outcome:censor"
18 outcome <-rbind(temp ,outcome)
19 outcome$start <-NA
20 test <-!is.na(outcome$Date)
21 outcome <-subset(outcome ,test)
22
23 ##if outcomes overlap , merge them.
24 ##this includes censored segements at end of dataset
25 ##cutoff is minumum gap between two outcomes in days
26 cutoff <-0
27 outcome_merged <-outcome [0,]
28 t.outcome <-outcome[!duplicated(outcome$id),]
29 for(i in 1: length(t.outcome$id)){
30 id<-t.outcome$id[i]
31 lstSeen <-cd$LstSeen[cd$id==id]
32 temp <-outcome[outcome$id==id & as.Date(outcome$Date) <=as.Date(lstSeen),]
33 temp <-temp[order(temp$Date) ,]
34 if(length(temp$id) >1){
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38 test <-temp2$DateResolution == latest
39 test <-ifelse(is.na(test),FALSE ,test)
40 latestResolution <-temp2[test ,"resolution"]
41 latestSurgeryLocResolution <-temp2[test ,"SurgeryLocResolution"]
42
43 if(length(latestResolution) >1){
44 latestResolution <-latestResolution [1]











54 temp <-temp[!is.na(temp$id) ,]




59 outcome_merged$outcome2 <-gsub("[[: space :]]no_outcome:censor","",outcome_merged$
outcome)
60
61 ##define periods leading up to analysis for outcome
62 ##start is start of analysis period: either diagnosis date + "observation_cut_
diag" or date of resolution of prior outcome - "observation_cut_outcome"
63 outcome_full <-outcome_merged [0,]
64 t.outcome <-outcome_merged[!duplicated(outcome_merged$id) ,]
65 for(i in 1: length(t.outcome$id)){
66 id<-t.outcome$id[i]
67 temp <-outcome_merged[outcome_merged$id==id ,]
68 for(j in 1: length(temp [,1])){














81 outcome_full <-rbind(outcome_full ,temp)
82 }
83





87 ##exclude outcomes which occur within 6 months of diagnosis.
88 outcome_full$DiagWithinSix <-NA








97 ##exclude outcomes which occur within 12 months of diagnosis.
98 outcome_full$DiagWithin12 <-NA








Definition of Independent Occurence of Fistula, Stenosis or Peroforation:
Merging observations of same complications
.4. Perianal fistula formation
Perianal fistulae were defined using data taken from dated perianal surgical pro-
cedures, dated perianal imaging procedures and dated clinical examinations of the
perineum. The following code defines how these data were transformed into a
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table which tabulates temporal progression from date of diagnosis to perianal fis-
tula formation, and when this fistula was deemed to have clinically resolved. The
resulting table is labelled outcome_full and has one or many lines per patient.
1 ## ’out ’ is the boolean vector which describes whether outcome has been met in
observed procedure








10 t.allNames <-c(t.clinNames ,t.radNames ,t.surgNames)
11
12 tt.out <-t.allNames[grepl(obs ,t.allNames)]
13 tt.date <-t.allNames[grepl("Date",t.allNames)]
14 ##’attribute ’ define outcome attribute (for stenosis this is radiological
upstream dilatation)
15 #attribute <-t.allNames[grepl (" StenosisD",t.allNames)]
16 #attribute2 <-t.allNames[grepl (" SurgeryL",t.allNames)]
17
18 ##define colnames of outvector
19 ##LocString is location of outcome eg. ’6,7’ (terminal ileum and caecum).
20 t.outNames <-c("id","Date","RadModality","Fistula","out","modality")
21
22 ##clean outcome field of interest (no text)
23 #note will need to review fields in this coding at a later date.
24 ##change 1 to 0 if it exists on it’s own in stenosis strings (likely coding error





28 ##(merge all modalities)
29 #########################
30 #RadPA





35 PAclinical$out <-ifelse(!(PAclinical[,t.clinNames%in%tt.out ]==0 | is.na(PAclinical
[,t.clinNames%in%tt.out])) ,1,0)
36 PAclinical$modality <-"clinical exam"















48 tt.outcome <-rbind(t.PAclinical ,t.PASurgery ,t.RadPA)
49 tt.outcome <-tt.outcome[!is.na(tt.outcome$Date),]
50




55 ##identify outcomes which qualify as independent outcome events , observed on
radiology , colonoscopy or surgery.
56 #########################
57
58 # An old outcome is one that has been identified previously on radiology ,
colonoscopy or at surgery , prior to time period defined by ’cutoff_passive_
independence ’ and ’cutoff_surgical_independence ’.
59 # A recent outcome is one identified within time period before the outcome
being assessed (as defined by ’cutoff_passive_independence ’ and ’cutoff_
surgical_independence ’).
60 # ’cutoff_passive_independence ’ is used to assess whether most prior outcomes are
’old ’ or ’recent ’.
61 # If a prior outcome is surgical resection of affected segment ,’cutoff_surgical_
independence ’ is used to assess whether it is ’old ’ or ’recent ’.( this cutoff
is shorter , acknowledging that surgery usually resolves stenosis/fistulae).
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73
74 for (i in 1: length(cd[,1])){
75 id<-cd$id[i]
76 t.temp <-tt.outcome[tt.outcome$id==id ,]
77 t.temp <-t.temp[order(t.temp$Date),]
78




83 if(length(t.temp [,1]) >1){
84 for (j in 2: length(t.temp [,1])){
85 ##in the ’cutoff_surgical_independence ’ period before this test , was an outcome
observed? (whether or not there has been intervening surgery).
86 t.comparePassive <-subset(t.temp ,as.Date(t.temp$Date[j])-as.Date(t.temp$Date)<
cutoff_passive_independence & as.Date(t.temp$Date[j])-as.Date(t.temp$Date) >
0 & t.temp$out ==1)
87 ##code only independent outcomes as ’1’ in
88 t.temp$outcome[j]<-ifelse(t.temp$out[j]==0 | length(t.comparePassive [,1]) >0,0,1)
89 }}}
90 t.temp2 <-subset(t.temp ,t.temp$outcome ==1)
91 t.temp2 <-subset(t.temp2 ,!duplicated(paste(t.temp2$id ,t.temp2$Date)))
92 tt.outcome2 <-rbind(tt.outcome2 ,t.temp2)
93 }
94 tt.outcome2$outcomeID <-c(1: length(tt.outcome2 [,1]))
95






102 ##definition of resolution of outcome:
103 ##subsequent surgery resecting affected segment of bowel within ’surgical_
resolution_cutoff ’; or
104 ##Once "passive_resolution_cutoff ’ time has passed without recurrent observation
of stenosis.
105
106 ##add colnames needed for resolution data.
107 t.resolutionNames <-c("DateResolution","resolution")




112 for (i in tt.outcome2$outcomeID){
113 ##reset resolution vector to NA
114 t.resolution <-NA
115 ##id of patient for this outcome event
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116 t.id<-tt.outcome2$id[tt.outcome2$outcomeID ==i]
117 ##isolate outcome event
118 t.out <-tt.outcome2[tt.outcome2$outcomeID ==i,]
119 t.temp <-tt.outcome[tt.outcome$id==t.id ,]
120
121 #determine date of resolution (passive or surgical)
122 ##resMarker: 1 means that this investigation demonstrates that the outcome being
observed has not yet resolved: 0 means that it has resolved (over <
passive_resolution_cutoff > has passed without observation of outcome).




126 t.len <-length(t.passRes [,1])
127 t.passRes$resMarker <-NA
128 t.passRes$resMarker [1] <-1
129 if (length(t.passRes [,1]) >1){
130 for (j in 2: length(t.passRes [,1])){
131 t.cutoff <-passive_resolution_cutoff
132 ##if t.cutoff hasn ’t passed , mark resMarker < 1 >.






138 ##mark resMarker2 as < 1 > for the last investigation that observes the
unresolved outcome.
139 t.passRes$resMarker2 <-NA
140 for (j in 2: length(t.passRes [,1])){




145 ##for the last observation , mark resMarker2 as < 1 > if patient has been









153 ##select resolution observation ( where resMarker2 = 1 )
154 t.resolution <-subset(t.passRes ,!is.na(t.passRes$resMarker2)&t.passRes$
resMarker2 ==1)
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155 ##assign date of resolution (after appropriate resolution cutoff period has
passed).





160 t.resolution <-c(t.end ,"no_resolution")
161 }
162 }
163 ##above nested code assigns resolution where more than one observation exists
after the initial obse rvation. For those with only the initial observation ,
code below assigns resolution dependant on whether < resolution cutoff > has
























186 temp[,cols [4: length(cols)]]<-NA
187 temp$outcome <-"no_outcome:censor"
188 outcome <-rbind(temp ,outcome)
189 outcome$start <-NA
190 test <-!is.na(outcome$Date)
191 outcome <-subset(outcome ,test)
192
193 ##define periods leading up to analysis for outcome
194 ##start is start of analysis period: either diagnosis date + "observation_cut_
diag" or date of resolution of prior outcome - "observation_cut_outcome"
195 outcome_full <-outcome [0,]
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196 t.outcome <-outcome[!duplicated(outcome$id),]
197 for(i in 1: length(t.outcome$id)){
198 id<-t.outcome$id[i]
199 temp <-outcome[outcome$id==id ,]
200 for(j in 1: length(temp [,1])){













214 outcome_full <-rbind(outcome_full ,temp)
215 }
216
217 #outcome_full <-subset(outcome_full ,!(outcome_full$DiagWithinSix | outcome_full$
ShortObs))
Listing 29
Definition of Independent Occurence of Perianal Fistulae
.5. Smoking status
This function defines whether or not a patient was smoking at a defined timepoint.
1 fun_smoking <-function(dataframe ,datefield){
2 ##Smoking status at datefield
3 #0=never , 1=ex-smoker , 2= current
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Listing 30
Definition of smoking status
